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1. Abstract 
The p63 transcription factor, homolog to the p53 tumour suppressor, plays a key role in limb, 
epithelial and cranio-facial development. p63 activity and stability are tightly modulated to guarantee 
correct development of such structures and an impairment of this regulative mechanism can result in 
severe malformations. The control of p63 function is achieved not only through the regulation of its 
gene expression but also through a complex network of post-translational modifications. Acetylation, 
phosphorylation and ubiquitination affect p63 half-life, the specificity and efficiency of protein-
protein interactions and overall modulate the transcriptional activity of the protein.  
Here we describe two pathways that, by post-translationally modifying ΔNp63α protein, modulate its 
stability and function. 
One such pathway involves FGF8, c-Abl and p300 which cooperate in controlling the stability and 
function of ΔNp63α protein by leading to its acetylation on lysine 193 (K193). Interestingly, K193 is 
mutated into glutamic acid (K193E) in patients affected by Split Hand/Foot Malformation (SHFM) 
type 4. c-Abl kinase activity is required to transduce the signal induced by FGF8 leading to ΔNp63α 
stabilization and transcriptional activation, through its acetylation mediated by p300. The ΔNp63α-
K193E mutant, which cannot be acetylated by this pathway, displays promoter-specific loss of DNA 
binding activity and consequent altered expression of development-associated ΔNp63α target genes. 
Our results, elucidating an important regulatory pathway activated by FGF8 and essential for ΔNp63α 
activation and stabilization, shed new light on the molecular mechanism that could be at the basis of 
the SHFM4 pathogenesis. 
The other pathway that we here present is a degradative pathway promoted by the teratogenic drug 
thalidomide that leads to proteasome-mediated degradation of ΔNp63α, resulting in a lack of 
activation of ΔNp63α development-related target genes. In cell lines, thalidomide treatment induces 
a downregulation of ΔNp63α protein via the action of GSK3 kinase and FBWX7 ubiquitin ligase. 
Upon thalidomide treatment, GSK3 kinase is required to phosphorylate ΔNp63α on the residues 
serine 383 and threonine 397. This phosphorylation is recognized as a signal by FBWX7 which in 
turn ubiquitinates ΔNp63α, leading to its proteasome-mediated degradation. Thalidomide treatment 
induces a downregulation of ΔNp63α protein levels also in vivo in zebrafish embryos, where it results 
in a phenotypical and molecular impairment of fin development. Importantly, the microinjection of 
zp63-mRNA into zebrafish embryos treated with thalidomide rescues both the phenotypical and 
molecular defects induced by the drug, indicating that the downregulation of ΔNp63α is, at least in 
part, at the bases of thalidomide-induced malformations. Our results, by demonstrating that ΔNp63α 
is a molecular target of thalidomide teratogenicity, provide a fundamental missing piece in the 
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description of the drug molecular mechanism of action. Thalidomide is now used for the treatment of 
multiple myeloma and leprosy: a better understanding of its mechanism of action might pave the way 
for the design of related compounds with equal therapeutic properties but devoid of teratogenic 
activity. 
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2. State of the art 
2.1 The p53 family 
p53, located on chromosome 17 (17p13), is the principal tumor-suppressor gene, being mutated in 
50% of human cancers (1). The p53 protein exhibits high amino acid identity with the other members 
of the family, p63 and p73, which are encoded by two genes located respectively on chromosome 3 
(3q27-29) and 1 (1q36). The highest identity among the protein of the family is in their 
TransActivation (TA) domain, DNA-Binding Domain (DBD), and tetramerization (ISO) domain. 
Unlike p53, p63 and p73 are not classical tumour suppressors, rather, they act as key regulators in 
development. p73 is involved in the development of neuronal and pheromonal pathways (2) and p63 
in limb, epithelial, and craniofacial development (2,3). p73 KO mice display high mortality rate 
within 2 months after birth, suffering from hydrocephals, indicative of abnormal cerebrospinal fluid 
dynamics, immunological problems characaterized by chronic infectious and inflammation and 
nervous system abnormalities related to hippocampal dysgenesis, olfactory neuron defects and loss 
of sympathetic neurons (4). p63-/- mice are born alive, but they die soon after birth because of 
dehydration. Moreover, they display an impairment in limb development as well as of stratified 
epidermis and of other ectodermal derivatives such as salivary, lacrimal and mammary glands, 
prostate, teeth and hair follicles (2,3). 
p63 and p73 encode several different isoforms. Both p63 and p73, encode two primary transcripts, as 
they can be transcribed under two different promoters: one is located in a non-coding region of exon 
1 and the other in intron 3. The product of the first promoter contains the TA domain (the TA isotypes) 
whilst the product of the second promoter lacks this domain (the ΔN isotypes). Additionally, 
extensive alternative splicing involves the 3’ end, resulting in five different variants for p63 (α, β, γ, 
δ, ε) and seven for p73 (α, β, γ, δ, ε, ζ, η). 
 
2.2 The p63 transcription factor 
2.2.1 Protein structure  
All p63 isoforms contain the DNA-binding domain (DBD), which is rensponsible for the binding of 
p63 to its responsive elements and the tetramerization (ISO) domain that allows the formation of 
omo- and etero-tetramer, which is essential for p63 transactivational functions.  
On the contrary, the transactivation (TA) domain is present only in the products of the promoter 
contained in exon 1 (TA isoforms). It was initially considered as the only responsible for the 
activation of p63 target genes. In fact, the ΔN isoforms were thought to act as dominant-negative 
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isoforms, which, lacking the TA domain, inhibited the transactivational function of the tetramer. 
However, it has been demonstrated that also the ΔN isoforms were able to modulate directly p63 
target genes as they possess a second transactivation (TA2) domain, located between the aminoacids 
410 and 512 (5). The extended 3’ coding sequences of the α-isoforms of p63 encode a protein-protein- 
interaction motif that resembles the sterile-α-motif (SAM) domain (6,7), which is not present in p53. 
SAM domains are small globular protein-protein interaction modules that are usually involved in 
homo- and hetero-oligomerization with other SAM domains. In the extended carboxy-terminal 
portion of α-isoforms is also present a C-terminal inhibitor domain (TID) which is able, by binding 
to the N-terminal region of the protein, to mask the TA domain, leading to a reduction of the 
transactivational activity of TAp63α isoform. 
Besides these major structural protein motifs, all p63 isoforms present, in the N-terminal portion, 
proline-rich domains, which are involved in pro-apoptotic activity and in the capacity to activate 
target sequences (8). A second proline-rich region is located between the ISO and SAM domains in 
p63 and p73 but not in p53. This proline-rich domain is engaged in a physical association with the 
YES-associated protein YAP (9) (Fig. 1). 
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Figure 1. Structure and expression of p53 family members. (a) Structure of p53, p63 and p73 transcription units. 
Numbered boxes indicate exons, and black shading denotes untranslated sequences. The approximate regions encoding 
the transactivation (TA) domain (light blue), N-specific region (green), DNA-binding domain (red), oligomerization 
domain (yellow), sterile alpha motif (SAM, grey), and transactivational inhibitory domain (TID, orange) are indicated. 
Distinct transcription start sites are indicated by arrows. N-terminal alternative splicing for p53 and p73 are indicated by 
dotted lines, and C-terminal splicing events are indicated by solid lines and Greek letter designation. (b) Protein domains 
of p53 family members. All three family members share a homologous DNA-binding domain and oligomerization domain 
(oligo). The TA domain is shared by p53, TAp63, and TAp73 isoforms. TAp63 /TAp73  isoforms most closely 
resemble p53. N-terminally truncated N isoforms possess unique N-terminal sequences. Alpha isoforms of p63 and p73 
possess a C-terminal SAM domain followed by a transactivational inhibitory domain (TID). Other isoforms of p53, p63 
and p73 are not shown (10). 
 
2.2.2 p63 expression and functions 
Despite the homology between p53 and p63, the latter is not considered a classical tumour suppressor, 
rather it has a key role in limb, craniofacial and epithelial development. In fact, mice lacking p63 are 
born alive but have striking developmental defects. Their forelimbs are truncated and hindlimbs are 
completely absent (2,3). These limb defects are caused by a failure of the Apical Ectodermal Ridge 
(AER) to differentiate. AER is a structure of stratified ectoderm with a key role in limb bud emergence 
and progression; sections of p63-/- specimens provide no evidence of a discernible stratified ectoderm 
along the interface of dorsal and ventral surfaces of the limb bud.  Instead, mutant limb buds have a 
single-layered epithelium at the distal tip, indistinguishable from the surrounding ectoderm. 
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Moreover, p63 KO mice die soon after birth because of dehydration as p63-/- mice lack epidermis. 
They also have no squamous epithelia (prostate, urothelium) or epithelial appendages, such as 
mammary, salivary and lachrymal glands, hair follicles and teeth (Fig. 2).  
The phenotype of p63 KO embryos correlates well with its pattern of expression. 
p63 is expressed as early as embryonic day 9.5 (E9.5) within the oral ectoderm, limb buds and tail 
bud region. At later stages of gestation, p63 is expressed primarily within the ectoderm; expression 
is evident within the basal region of the interfollicular epidermis of the skin and within the outer root-
sheath of hair follicles. In adult mice, p63 is expressed in skin, tongue, tail and skeletal muscle. 
 
 
Figure 2. The phenotype of p63-deficient newborn mice. (a) Matings between p63-heterozygous mice produce wild-type 
and heterozygous offspring that are overtly normal and p63-deficient mice that have severe limb and skin defects. (b) 
Skeletons of wild-type, p63-heterozygous and p63-homozygous mutant animals were stained for cartilage (blue) and bone 
(red). (c) Forelimbs of p63-homozygous mutant mice are truncated; the phalanges, radius and ulna are absent and the 
humerus is deformed. Abbreviations: c, clavicle; h, humerus; r, radius; s, scapula; u, ulna (3). 
 
 
2.2.3 Conserved sequence and role for the p63 gene in zebrafish (Danio rerio)  
In 2002, Bakkers et al. (11) cloned three different p63 isoforms in zebrafish, all encoding for ΔNp63 
proteins lacking the N-terminal transactivating (TA) domain. In their C terminus, the two longer 
ΔNp63 isoforms (α1 and α2) correspond to the mammalian α splice products, containing the SAM 
domain and the entire C-terminal tail, while the shorter isoform corresponds to γ splice variants, with 
a C-terminal truncation starting before the SAM domain. The amino acid sequence alignment 
demonstrates that ΔNp63α is highly conserved from fish to mammals (11,12). Of the major domains 
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identified in p63, the DNA binding domain is 96% identical, the oligomerization domain is 67% 
identical and the SAM domain is 68% identical between mouse and zebrafish (11) (Fig. 3). 
 
 
 
Figure 3. Diagram of isolated p63 isoforms. Structure of the longest version of mouse p63 and the three isolated zebrafish 
ΔNp63 isoforms. TAD, transactivating domain; DBD, DNA binding domain; OD, oligomerization domain; SAM, sterile 
α motif. Numbers indicate the percentages of amino acid conservation of the different domains between mouse p63 and 
zebrafish ΔNp63α. Compared to ΔNp63α1, α2 lacks 12 amino acids at the indicated position upstream of the SAM domain 
(11). 
 
 
 
The ΔNp63α versions are the most abundant, if not the only, p63 isoforms present during zebrafish 
embryogenesis. ΔNp63 is readily detectable at early gastrula stages and continues to be expressed at 
similar levels during the first few days of embryogenesis (11,12) (Fig. 4).  
 
 
 
Figure 4. p63 temporal expression in zebrafish embryos. 
 
 
Whole-mount in situ hybridization revealed that ΔNp63 expression is confined to the ventral ectoderm 
of gastrula embryos, which will give rise to epidermal, non-neural fates.  Expression of ΔNp63 in the 
prospective epidermal ectoderm is maintained throughout late gastrulation and early segmentation 
stages. At around 40 hours post fertilization (hpf), ΔNp63 transcripts are present in the ectodermal 
components of the branchial arches and the pectoral fin buds. In the fin buds, ΔNp63 is only expressed 
in the distal tip, called apical fold, which is homologous to the AER of higher vertebrates and not in 
the underlying mesenchyme. ΔNp63 is also expressed in the cutaneous ectoderm (11,12) (Fig. 5). 
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Figure 5. Stain by whole-mount in situ hybridization with indicated probe (ΔNp63). (a) 80% epiboly, lateral view, dorsal 
right, animal pole (anterior) up. Arrows point to margin of embryos. (b) Tailbud stage, dorsal right. (c) 48 hpf, ventral 
view on head region. (d) 38 hpf, optical transverse section through fin bud and trunk; axes of fin bud are indicated; distal 
up, proximal down, ventral left, dorsal right. The arrowhead points to presumptive apical fold. (e) 38 hpf, optical saggital 
section through finbud; axes of fin bud are indicated; distal up, proximal down, anterior left, posterior right. (f) 48 hpf, 
view on pectoral fin; axes of fin bud are indicated; ventral up, dorsal down, proximal left, distal right; arrowheads point 
to apical fold (11). 
 
Consistent with the expression pattern of ΔNp63, its knock down in zebrafish embryos, obtained by 
microinjecting a specific morpholino, results in the absence of pectoral fins, probably due to the 
failure to maintain the apical fold. Moreover, skin lesions are noticeable and by days 4-5 post 
fertilization, the ΔNp63 morphants are susceptible to infection by microorganisms since the skin is 
no longer acting as a protective barrier from the outside environment. In morphant embryos skin cells 
fail to proliferate and are strongly reduced in number, but still express cytokeratin8, a marker for 
keratinocytes (11,12) (Fig. 6). 
Overall, the phenotype is intriguingly similar to the effects observed in mice lacking the p63 gene, 
suggesting a conserved role for p63 in limb and epithelial development.  
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Figure 6. MO-based zebrafish ΔNp63 knockdown affects pectoral fin and skin development. Upper panel of each block 
shows control animals injected with 4 mm MO; lower panel morphants injected with ΔNp63 MOs. (a-d, g, and h) live 
larvae; (e and f) in situ hybridization with indicated probe (zfk8). (a, b) 72 hpf, dorsal view on anterior region. Arrows 
in (b) point to missing pectoral fins. (c, d) 48 hpf, view on pectoral fin. The arrowhead in (c) points to apical fold 
missing in (d). (e, f) zfk8, 48 hpf, dorsal view on head. White arrowheads in (f) point to clusters of zfk8-positive cells. 
(g, h) 54 hpf, dorsal view on trunk/tail. Arrowheads in (h) point to blisters in skin (10). 
 
p63 overexpression in ΔNp63 mRNA-injected embryos results in severe anterior CNS truncations, 
due to extended apopotosis among anterior neuroectodermal cells. Thus, ΔNp63 mRNA-injected 
larvae lack forebrain and eyes, while other anterior structures like jaw and hatching glands and the 
rest of the embryo develop normally (11) (Fig. 7). 
 
 
Figure 7. 120 hpf, lateral view. (a) Uninjected control. (b) Animal injected with ΔNp63α mRNA. Arrowhead points to 
jaw (11). 
 
 
2.2.4 p63-associated syndromes and malformations  
The phenotype of p63 KO mice and zebrafish morphants correlates well with the defects displayed 
by patients affected by mutations in p63 gene. There is a wide spectrum of p63 mutations that underlie 
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five different human malformation conditions: Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) 
syndrome (MIM 604292), Ankyloblepharon-Ectodermal dysplasia-Clefting (AEC) syndrome (MIM 
106260), Limb-Mammary Syndrome (LMS [MIM 603543]), Acro-Dermato-Ungual Lacrimal-Tooth 
(ADULT) syndrome (MIM 103285), and nonsyndromic Split-Hand/Foot Malformation (SHFM) type 
4 (13). All these disorders are caused by dominant mutations; it is likely that p63 mutant protein 
perturbs the activity of the wild type ones with which it can form tetramers.    
It is noteworthy that the localization and functional effects of the mutations that underlie these 
syndromes establish a striking genotype-phenotype correlation (13,14) (Fig. 8). 
 
Ectrodactyly-Ectodermal dysplasia-Clefting (EEC) syndrome 
EEC are invariably affected by ectodermal dysplasia which can present as defects of hair, skin, nails 
teeth and glands. About two-thirds of these patients also have ectrodactyly, syndactyly is also frequent 
(43%). Cleft lip/palate is present in about 40% of the EEC patients, who occasionally also have 
mammary gland/nipple hypoplasia (14%) and hypohidrosis (11%). 
Altogether 34 different EEC causing mutations have been reported, and 20 different amino acids are 
involved. However, they are almost all missense point mutations in the DBD of the p63 gene and 
only two mutations are outside the DBD: one frameshift mutation consisting in a single nucleotide 
insertion in exon 13 (1572 InsA) and one point mutation (L563P) in the SAM domain. 
Five frequently mutated amino acids: R204, R227, R279, R280 and R304 in the EEC population 
explain almost 90% of the EEC syndrome patients. The five p63 arginine hotspot mutations appear 
to impair the p63 protein binding to DNA, resulting in loss of p63 transactivational activity (13,15).  
 
Limb-Mammary Syndrome (LMS) 
The LMS phenotype resembles the EEC syndrome phenotype; about 70% of LMS patients have 
similar limb malformations as in EEC syndrome, and about 30% display orofacial clefting. However, 
the ectodermal manifestations are milder. Moreover, unlike in EEC patients, hair and skin defects are 
rarely detected in LMS patients a consistent feature of LMS is the mammary gland and/or nipple 
hypoplasia (100%). Lacrimal duct obstruction and dystrophic nails are also frequently observed (59 
and 46% respectively), hypohydrosis and teeth defects are detected in about 30% of the patients. 
Mutations in LMS are located in the N- and C-terminus of the p63 gene. A large LMS family display 
G76W substitution in the ΔN-specific putative transactivation domain (TA2). One other missense 
point mutation (S90W) is located between the TA domain and DBD. In the C-terminus a TT deletion 
in the exon 13 and an AA deletion in exon 14 have been reported. These mutations will affect only 
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the p63α protein isoforms, where they are predicted to cause a frame shift and a premature stop codon. 
Also, a stop mutation in the TID (K632X) has been identified in a sporadic LMS patient and is 
predicted to impair the suppressive effect of the TI domain towards the TA domain, thus increasing 
p63 transactivational activity (13,15). 
 
Acro-Dermato-Ungual Lacrimal-Tooth (ADULT) syndrome 
As in LMS, ADULT syndrome phenotype is characterized by ectrodactyly and ectodermal defects, 
but hair (53%) and lacrimal duct defects (67%) are observed in ADULT patients more frequently than 
in LMS. Moreover, whilst teeth, skin and nail defects are only rarely observed in LMS, they are 
constantly present in ADULT syndrome (100, 93 and 100%, respectively). One other difference is 
the absence in ADULT syndrome of orofacial clefting. Four ADULT syndrome families and three 
sporadic cases have been reported. All the families and one of the sporadic cases have a missense 
point mutation in exon 8, changing R298 in the DNA binding domain into either a glutamine or a 
glycine. R298 is not located close to the DNA-binding interface, and mutation of this arginine does 
not affect DNA binding, but can confer transactivational activity to ΔNp63γ isoform. Two other 
mutations are located in the N-terminus: N6H mutation affects only the ΔN-isoforms and in another 
isolated patient a missense mutation G134D* is located just in front of the DBD in exon 4 (13,15). 
 
Ankyloblepharon-Ectodermal dysplasia-Clefting (AEC) syndrome 
Limb malformations are almost absent in AEC syndrome and ectrodactyly has never been reported, 
but 25% of patients have mild syndactyly. Approximately 80% of the patients have severe skin 
erosion at birth, which usually will recover in the first years of life. The eyelid fusion, also called 
ankyloblepharon, is present in about 45% of AEC patients. Nails and teeth defects are present in more 
than 80% of patients, and hair defects and/or alopecia are almost constant features (94%). Lacrimal 
duct obstruction is seen in 50% of patients, whereas mammary gland hypoplasia and hypohydrosis 
occur occasionally (both 13%). Interestingly, almost 40% of patients have hearing impairment and 
genito-urinary defects. Cleft lip is present in 44% and cleft palate in about 80%. 
Mutations in 12 unrelated patients with AEC have been detected, and 10 of these are missense 
mutations within the SAM domain of p63. These mutations are predicted to disrupt protein-protein 
interactions, by either destroying the compact globular structure of the SAM domain or by 
substituting aminoacids that are crucial for such interactions. Missense mutations in AEC syndrome 
affect only the α isotypes of p63 (13,15).  
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Nonsyndromic Split-Hand Foot Malformation (SHFM) type 4 
SHFM4 is a “pure” limb malformation (ectrodactyly and syndactyly) condition, thus without 
orofacial clefting or ectodermal dysplasia. SHFM is genetically heterogeneous, and three loci have 
previously been identified: 7q21-q22 (SHFM1), Xq26 (SHFM2) and 10q24 (SHFM3). In two 
affected families, SHFM chromosomal abnormalities did not map to any of these established loci but 
instead mapped to 3q27-q28, thereby indicating the existence of a fourth locus. Causative p63 
mutations were found in both families. 
Five of the seven p63 mutations seen in patients with SHFM are unique to this syndrome: missense 
mutations K193E and K194E, nonsense mutations Q634X and E639X, and splice-site mutation IVS4-
2ArC. Q634X and E639X are known to disrupt p63 sumoylation site, and therefore increase the 
stability and transcriptional activity of the p63α isoform. Two other mutations, R280C and R280H, 
have been found in both SHFM and EEC syndrome. This arginine is not in direct contact with the 
DNA, but the mutation might indirectly affect the DNA-binding capacity of p63 (13,15). 
 
 
 
Figure 8. Illustration of p63 mutations in human syndromes establishing a clear genotype-phenotype correlation (16). 
 
2.2.5 p63 downstream target genes  
p63 is a transcriptional factor with a key role in limb development and epithelial stratification. It is 
likely that p63 exherts its function by regulating at a transcriptional level a series of target genes with 
a role in these processes. Many phenotype-relevant transcriptional targets of p63 have been identified 
through classical “candidate gene” approaches or by genome-wide screenings (14). 
The best experimentally characterized function of p63 is to maintain the proliferative potential of 
epidermal progenitor cells. ΔNp63 can control distinct transcriptional networks depending on the 
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state of maturation of keratinocyte precursors. In proliferating keratinocytes of the basal layers, 
ΔNp63 promotes their amplification and controls the expression of basal layer keratins (K5, K14). 
Following a differentiation stimulus, ΔNp63 can change its transcriptional activity, activate genes 
required for cell cycle exit (IKKa and IRF6), and reorganize the transcription of adhesion molecules 
to allow keratinocytes to leave the basal layer and stratify (14).  
 
DLX3 
Many pieces of evidence suggest that a correct balance among different isoforms of p63 drives 
epithelial stratification. In particular, ΔNp63 is important for maintaining the proliferative potential 
of the basal layer, whereas TAp63 contributes by acting synergistically and/or subsequently to ΔNp63 
to allow differentiation (2,3,17–20). TAp63α, but not ΔNp63α, is able to transactivate distalless 
homeodomain transcription factor DLX3 (21). DLX3 is expressed exclusively in the suprabasal 
differentiated layers of epidermis (22,23) where it activates a molecular mechanism that targets 
ΔNp63α for proteasome-mediated degradation. p63 functions as a molecular switch that initiates 
epithelial stratification while regulating keratinocytes proliferation and differentiation; DLX3-
mediated ΔNp63α degradation may contribute to accomplish the program of terminal skin 
differentiation (24). 
 
IKKa 
IKKα is a protein kinase part of the IKK complex required for epidermal development and for the 
development of structures derived from the mesoderm and neural crest (25) and to switch on the 
differentiative program by favoring keratinocyte cell cycle arrest (26). IKKα is a direct transcriptional 
target of p63 in keratinocytes that is induced at early phases of terminal differentiation of primary 
keratinocytes (27,28). A failure by ΔNp63α to properly induce IKKa may play a role in the 
development of ectodermal dysplasias. Indeed, mutant p63 proteins expressed in ectodermal 
dysplasia patients exhibit defects in inducing IKKα (27). Consistently, Ikkα-deficient mice display 
developmental defects, including skin, craniofacial, and limb defects, showing some similarities with 
p63 null mice (2,3,29–31).  
 
IRF6 
IRF6 is a member of a family of interferon-dependent transcription factors (32) that control the 
proliferation-differentiation switch in epidermal cells (33–35); Irf6-null mice display an 
undifferentiated hyperplastic skin, due to the inability of Irf6 mutant cells to exit the cell cycle (33,34). 
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IRF6 is also required for palate closure: mutations in IRF6 are linked to a set of syndromes related to 
ectodermal dysplasia (36). IRF6 has been demonstrated to be a ΔNp63 direct target gene. There is a 
feedback regulatory loop between IRF6 and p63, in which p63 controls IRF6 transcriptionally, while 
IRF6 controls p63 at the protein-stability level. IRF6 expression is required to allow the onset of 
terminal differentiation by promoting the proteasome-dependent degradation of ΔNp63 (14,37). 
 
REDD1 
REDD1 is a transcriptional target of p63 which appears to function in the regulation of reactive 
oxygen species (ROS). During mouse embryogenesis, Redd1 mirrors p63 tissue-specific pattern and 
in differentiating primary keratinocytes p63 and Redd1 expression are coordinately downregulated. 
p63-null embryos show no expression of Redd1 and loss of p63 alters cellular ROS levels (38). In 
addition to effects on cellular stress and viability, subtle shifts in intracellular ROS levels can 
modulate cellular signalling through multiple tyrosine kinase growth factor receptors, including the 
epidermal growth factor receptor (EGF-R) (39–41). Regulation of EGF-dependent responses by ROS 
may therefore contribute to the effect of p63 on keratinocyte differentiation. 
 
P-cadherin 
P-cadherin (CDH3 in human) is a cell-cell adhesion molecule, whose expression is highly associated 
with undifferentiated cells in normal adult epithelial tissues and is considered a marker of stem or 
progenitor cells of epithelial tissues (42,43). P-cadherin has been shown to be a transcriptional target 
of p63 (44), and is the disease gene for the Ectodermal Dysplasia-Ectrodactyly-Macular Dystrophy 
syndrome (EEM, MIM 225280) (45,46), characterized by the presence of the SHFM phenotype. 
However, no limb developmental functions of P-cadherin have been shown in mice (42).  
 
PERP 
PERP is a tetraspan membrane protein which, during embryogenesis, is expressed in an epithelial 
pattern, and its expression depends on p63. Perp-/- mice die postnatally, with dramatic blistering in 
stratified epithelia symptomatic of compromised adhesion. PERP localizes specifically to 
desmosomes, adhesion junctions important for tissue integrity, and numerous structural defects in 
desmosomes are observed in Perp-deficient skin, suggesting a role for PERP in promoting the stable 
assembly of desmosomal adhesive complexes. PERP is a direct p63 target gene, positively regulated 
by both TAp63 and ΔNp63 isoforms and is a key effector in the p63 developmental program, playing 
an essential role in an adhesion subprogram central to epithelial integrity and homeostasis (47). 
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DLX5 and DLX6 
It is possible to link the role of p63 in epithelial stratification with its function in limb development. 
In fact, the AER, the ectodermal structure at the distal tip of the developing limbs essential for limb 
bud expansion and morphogenesis, is perhaps the first attempt of the embryonic ectoderm to organize 
into a multi-layered epithelial tissue (48). Indeed, the AER of p63 null mice fails to organize as 
multilayer and there is experimental evidence that a failure to maintain the AER is the main 
pathogenic mechanism in the onset of the ectrodactyly phenotype (48,49). 
Distalless-related homeogenes DLX5 and DLX6 are direct ΔNp63α transcriptional targets, whose 
regulation during limb development is needed to maintain the specialization and stratification of the 
AER cells; deletions of DLX5 and DLX6 can cause SHFM type 1 (14,50). In the limb buds of both 
p63 and Dlx5;Dlx6 murine models of SHFM, the AER is poorly stratified and FGF8 expression is 
severely reduced (51). In zebrafish embryos, p63-knockdown obtained by microinjecting a specific 
p63-morpholino causes a strong reduction in the expression of the zdlx5a and zdlx6a genes along with 
severe fin buds defects (52). 
Furthermore, EEC and SHFM4 p63 mutants fail to transcriptionally activate DLX5 and DLX6 (50).  
 
 
2.3 Limb development 
 
As mentioned above, p63 plays a key role in limb development. This is a delicate process driven by 
a complex network of several genes that control the correct timing and localization of limb 
morphogenesis. 
The fore- and hind-limb buds emerge at defined somite positions perpendicular to the primary body 
axis because of continued growth of the flank mesoderm. The developing limb bud is a large 
embryonic field whose cells receive proliferative and positional cues from signals that allow their 
patterning along three axes: the Antero-Posterior (AP), Dorso-Ventral (DV), and Proximo-Distal 
(PD) axes. Three main limb skeletal compartments characterize the PD axis: the proximal stylopod, 
followed by the zeugopod and the distal autopod. The AP limb axis is congruent with the primary 
body axis and manifests itself in the distinct identities of the digits bearing autopod. Five distinct 
digits form in mice and humans with digit 1 (thumb) having the most anterior and digit 5 (little finger) 
the most posterior identities. It is generally accepted that the identities of the limb skeletal elements 
reflect the establishment of positional identities during limb-bud development (53–57) (Fig. 9). 
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Figure 9. Skeletal preparation of a mouse forelimb at birth. Red and blue histological stains mark ossified bone and 
cartilage, respectively. (Proxdist) Proximodistal axis, (ant-post) anteroposterior axis, (Sc) scapula, (Cl) clavicle, (Hu) 
humerus, (Ra) radius, (Ul) ulna. Digit identities are indicated by numbers (57).  
 
 
The first step in the development of a vertebrate limb is the determination of a group of embryonic 
cells that will give rise to the limb primordium (or limb bud). These so-called limb fields are initially 
composed of cells within the Lateral Plate Mesoderm (LPM) that are located in specific positions in 
the flank of the embryo by a combinatorial HOX genes expression which is in turn controlled by 
Retinoic Acid (RA) (58). 
After the forelimb and hindlimb fields have been specified at precise locations along the embryonic 
flank, the corresponding cells in the LPM engage in active cell division, whereas cells in the non-
limb flank LPM divide more slowly (59). This differential cell proliferation results in the development 
of a noticeable limb bud, consisting of a mass of mesenchymal cells encased in an ectodermal jacket. 
The mesenchymal cells of the prospective forelimb and hindlimb areas widely express FGF-10. FGF-
10 protein signals to the overlying ectoderm to initiate a program of gene expression that includes 
activation of FGF-8 transcription. These inductive signals from LPM cells of the limb bud area induce 
the overlying ectoderm to form a specialized structure (the AER), an ectodermal thickening that runs 
along the AP axis of the limb bud, separating the dorsal side of the limb from the ventral side (56).  
The establishment of the AER is the first step in the definition of the limb PD patterning. 
 
2.3.1 Proximo-distal patterning 
On the basis of the experimental evidence, many models were proposed to explain the processes that 
end up with the definition of the proximo-distal identities in the limb.  
The progress zone model states that acquisition of PD identities depends on the time spent by 
proliferating undetermined cells in the distal mesenchyme (progress zone) under the influence of 
AER signals. As the progress zone is displaced distally, the more proximal cells are no longer under 
the influence of the AER, which causes determination of their positional identities. Mesenchymal 
cells “left behind” early acquire more proximal identities, whereas progenitor cells staying under 
influence of the AER longer acquire progressively more distal identities (60). 
Part I 
17 
 
Another model accepted as a valid alternative to the progress zone model is the model proposed by 
Mercader et al. in 2000 (61).  According to this model, PD limb-bud identities are specified by two 
early, opposing signals, namely RA, which is emanating from the embryonic flank/proximal limb 
bud, and AER-FGFs as proximalizing and distalizing signals, respectively. PD positional identities 
are likely specified as a consequence of cells integrating these signalling cues. During the onset of 
limb-bud development, the source of RA and AER-FGFs are very close, but their distance increases 
with outgrowth of the limb bud, such that proximal cells are exposed to RA for much longer than 
AER-FGFs, whereas the reverse applies to distal cells. In 2007, Tabin and Wolpert (62) proposed a 
modified model in which distal mesenchymal cells maintain an undifferentiated state during the 
proliferative expansion of the PD axis, because of exposure to AER-FGFs. As the PD limb axis 
expands distally, proximal mesenchymal cells are no longer under the influence of AER-FGFs, which 
results in the determination of their PD fates and initiation of differentiation. Therefore, the proximal 
limit of cells receiving AER-FGF signals at a given development time point defines a “differentiation 
front.” This differentiation front prefigures the PD sequence by which the chondrogenic elements of 
the limb skeleton become apparent during subsequent mesenchymal condensation of the cartilage 
models.  
 
2.3.2 Antero-posterior patterning 
Growth and patterning along the AP axis appear to be tightly coordinated with the development of 
the PD axis, in a process mediated by specific interactions between the controller of limb outgrowth 
(the AER) and the AP organizer (the Zone of Polarizing Activity; ZPA). The ZPA is composed of a 
group of cells located in the posterior mesenchyme of the limb bud (63). In 1969 Wolpert (64) 
proposed that the ZPA specifies positional information in the limb-bud mesenchyme by secreting a 
diffusible molecule that forms a posterior (high) to anterior (low) gradient. Wolpert’s model became 
famous as the “French Flag model” as it proposes that mesenchymal cells receive their positional 
identities by responding to specific thresholds of the morphogen gradient (Fig. 10). 
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Figure 10. Wolpert’s French flag model: A concentration gradient forms by diffusion of a morphogen from a source and 
positional information is determined in groups of cells by inducing distinct responses to specific concentration thresholds 
(indicated by blue, white, and red) (57). 
 
In 1993, it was shown that the polarizing activity of the ZPA is mediated by Sonic hedgehog (SHH) 
(65–67), a gene that encodes a secreted factor homologous to the product of the Drosophila segment 
polarity gene hedgehog (hh), involved in many patterning processes in the embryo and imaginal discs 
(68). As first shown in the chick embryo, Shh expression is detected at stage 17 in the posterior margin 
shortly after the limb bud is induced, co-localizing with the ZPA. A similar pattern is observed in 
mouse, zebrafish, and other vertebrates (69–71). It is thought that SHH functions as a morphogen, 
possibly through an inductive effect on BMP2 expression, and that the distance it diffuses depends 
upon post-translational modifications (72,73). The molecular mechanism by which SHH signalling 
regulates its target genes involves effects on GLI3, which functions either as transcriptional activator 
(GLI3A) or repressor (GLI3R). High levels of SHH prevent the formation of GLI3R and promote 
GLI3A function. Thus, the local concentration of SHH regulates target gene expression by controlling 
the balance of GLI3 repressor and activator forms (74,75). 
SHH is not involved in patterning the most proximal limb structures, but SHH activity is absolutely 
required for the maintenance of growth and patterning of intermediate and distal limb structures and 
for the maintenance of the AER (56,76,77). In turn, maintenance of SHH expression in the posterior 
margin of the limb bud requires the integrity of the AER. Thus SHH seems to act in a regulatory loop 
with FGF proteins expressed in the AER to maintain cell growth and proliferation in the mesenchyme, 
and to maintain the integrity of the AER (78,79). 
 
2.3.3 Dorso-ventral patterning 
During limb development, DV patterning requires complex interactions between the ectoderm and 
mesoderm (80). Once DV patterning is established in the ectoderm, then it is the ectoderm that 
imposes the DV information on the mesoderm (80–82). The specification of DV polarity in the 
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ectoderm results in the establishment of specific domains of gene expression. The secreted factor 
encoded by the gene WNT7a is specifically expressed in the dorsal limb ectoderm and acts as a 
dorsalizing factor by imposing the expression of LMX1b, a LIM homeodomain-containing gene, in 
the underlying dorsal mesoderm (83–87). BMP signals, probably from the lateral mesoderm, are 
crucial for ventral patterning since they induce the expression of Engrailed 1 in the ventral ectoderm, 
which acts to confine WNT7a expression to the dorsal ectoderm (88–90). This occurs in a narrow 
temporal window immediately prior to the initial outgrowth of the limb bud (91,92). 
 
 
2.4 Fin development 
 
Zebrafish paired pectoral fins and tetrapod limbs are considered to be homolog structures, in 
particular with respect to early patterning and gene expression (93). Numerous factors essential for 
limb development are involved with very similar functions in fin development. Fgf signalling is 
essential for limb outgrowth and it also plays crucial roles in pectoral fin bud formation. Fgf10 is 
expressed in the mesenchyme of the pectoral fin bud-forming region and is required for pectoral fin 
bud outgrowth (94). Fgf8 is also expressed in the AER of pectoral fin buds and plays a role in the 
pectoral fin bud formation (95). Likewise, a requirement for the essential antero-posterior organizing 
factor shh has been demonstrated in cell proliferation in the zebrafish pectoral fin bud (96,97). 
Nevertheless, zebrafish fins and tetrapod limbs have obvious morphological differences in the skeletal 
structures. The paired pectoral fins of teleost fish contain two different bone elements. Endoskeletal 
elements are formed as chondral bone through endochondral ossification; exoskeletal elements (fin 
rays) are formed by intramembranous ossification (98). Fin rays are unique to, and common in, the 
fins of actinopterygians (e.g. teleosts) and basal sarcopterygians but this structure is never seen in 
tetrapod limbs. The endoskeletal elements proximal to fin rays in the teleost pectoral fin are poorly 
patterned along the PD axis, whereas limb endoskeletal elements exhibit a well-organized sequential 
pattern (stylopod, zeugopod and autopod) (99). Therefore, limb evolution involved both better 
endoskeletal element patterning and the elimination of fin rays. Many studies suggest that fin 
structures transformed into limbs by changes in genetic and developmental programs during tetrapod 
evolution (100–105). One major difference between fin and limb development is that the AER, which 
organizes limb development, in the fin bud transitions into a different, elongated organizing structure, 
the Apical Fold (AF) from the middle stage of fin development (106). 
In zebrafish embryos it is possible to recognize a thickened single layer epidermis, a typical 
morphological trait of the AER, as early as at 30 hpf. By 34 hpf, the AER forms a small notch where 
two sheets of epidermis approach each other. At 36 hpf the notch starts to extend and makes a slit, 
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dividing the two epithelial layers. This distinctive morphological change marks the transformation of 
the AER into the AF. From now on, AF expresses fgf4 and fgf8, which are AER markers in the 
amniote limb and starts growing considerably in the distal direction.  
By 46 hpf, the distal fin mesenchyme starts migrating into the base of the AF, and continues to invade 
distally in a slit between the two layers of the AF. At 56 hpf, it is possible to distinguish between two 
portions of the AF with different tissue organization and gene functions: a distal region containing no 
mesenchyme (distal AF, dAF) and a proximal region with migrating mesenchyme (proximal AF, 
pAF) (107) (Fig. 11).  
 
 
 
Figure 11. AER-AF transition and morphological features in pectoral fin development. (a-g) A series of transverse 
pectoral fin bud sections (distal is to the right and dorsal is to the top) at the indicated stages. The basement membrane 
(red), shown by Laminin α5 immunostaining, is located between the ectoderm (e) and mesoderm (m) (a). Cell nuclei are 
visualized by DAPI (white). The distal portion of the AF (magenta brackets) consists of ectodermal cells only, and 
mesenchymal cells (asterisks) enter the notch of the AF within the proximal AF region (green brackets). The 
circumferential fin blood vessel (white arrows) is located at the base of the AF (e-g), and is recognizable by GFP 
distribution in fli1:EGFP y1 transgenic fish (g). ed, endoskeletal disc. Scale bar: 50 μm. (h) Diagram of transverse fin bud 
sections during AER/AF morphogenesis (107). 
 
In contrast to what it happens in the tetrapod limb bud, where AER removal results in distal truncation 
of the limbs, in zebrafish embryos, repeated AF removal elongates the endoskeletal region along the 
PD axis. Interestingly, cellular proliferation status changes by AF removal. Mesenchymal cell 
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proliferation increases beneath a newly formed AER, which sends signals for morphogenesis into the 
endoskeletal region. The nature of these ectodermal signals remains unknown. AER signals before 
the transition are necessary for the survival, growth and maintenance of an undifferentiated state of 
‘mesenchyme’, and experimental evidence suggest that dAF at the apex of the expanding AF might 
have the same function against the pAF. In fact, as fin development proceeds, dAF is distanced from 
the endoskeletal region and cannot continue to regulate its morphogenesis. Therefore, the region 
responding to the epidermal signals should change from the endoskeletal region to the pAF region at 
the time of the AER-to-AF transition (107) (Fig. 12).  
 
 
 
Figure 12. A model of pectoral fin development. (a) Until 36 hpf, the AER (red) is crucial for fin mesenchyme outgrowth 
(straight arrow). (b) After AER-AF transition, the dAF acts on the outgrowth of the AF (curved arrows). (c) Later, the 
dAF is distinguished from the pAF by tissue organization and gene expression. As fin buds develop distally, the 
ectodermal cell shape in the AF changes from a spherical and slender morphology (b) to a thin, polygonal one (c). 
 
In this scenario, a heterochronic shift of the timing of AER-to-AF transition in evolution (the so-
called clock model) (108) might explain fin-to-limb transition. In teleost fins, AER signals regulate 
endochondral skeletal patterning during a short period of early fin development, resulting in a poor 
endoskeletal pattern; then the AF forms and fin rays develop. On the contrary, in tetrapod limbs, 
where AER signals regulate skeletal patterning through the entire period of limb development and an 
AER-to-AF transition never occurs, the proximal mesenchyme is exposed longer to AER signals, 
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resulting in a better patterning of endoskelatal elements and fin rays never develop (107,109) (Fig. 
13). 
 
 
 
Figure 13. Clock model hypothesis. Hypothesized images of fin/limb development in the clock model (above), and 
endoskeletal patterns of the fin/limb (below). In teleost fins (left-most panel), AER signals regulate endochondral skeletal 
patterning during a short period of early fin development, resulting in a poor endoskeletal pattern; then the AF forms and 
fin rays develop. In the fins of lobe-fin fish (such as coelacanths and lungfish), basal actinopterygians (such as paddlefish 
and sturgeons) and chondrichthyans (such as sharks and skates, middle panel), regulation by AER signals continues for a 
longer period than in teleost fins, resulting in a better endoskeleton pattern and in the eventual transformation of the AER 
into the AF. In tetrapod limbs (right-most panel), AER signals regulate skeletal patterning through the entire period of 
limb development, an AER-to-AF transition never occurs, and fin rays never develop (107). 
 
 
2.5 Thalidomide 
 
Fifty years ago, the prescription of thalidomide to pregnant women caused a worldwide epidemic of 
multiple birth defects (Fig. 14).  
Thalidomide (α-phthalimidoglutarimide) was developed and launched on the market by the German 
pharmaceutical company Grunenthal in 1957. Apparently, at that time, the drug had already been 
tested on rodents without observing any remarkable toxicity. Thalidomide was distributed and 
prescribed as a sedative and an antidote against morning sickness in over 40 countries. However, 
already in 1961 and 1962, two independent studies by W. McBride in Australia and W. Lenz in 
Germany reported limb and bowel malformations in children born to mothers who were exposed to 
thalidomide during pregnancy (153–159). The drug was immediately withdrawn from the market but 
many studies continued to investigate the mechanism of thalidomide action. 
 
Figure 14. Child born to mother exposed to thalidomide during pregnancy. 
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Further investigation led to the discovery of several remarkable clinical effects of the drug which 
extended far beyond its sedative properties. In 1965, the Israeli physician, Sheskin, found thalidomide 
to be effective for the treatment of Erythema Nodosum Leprosum (ENL), an inflammatory 
complication of leprosy that results in painful skin lesions (160).  
During the 1980s and early 1990s, investigators found that thalidomide was an effective treatment 
for certain autoimmune disorders, such as chronic graft versus host disease and rheumatoid arthritis 
(161–165). In the early 1990s, it was reported that thalidomide inhibits the production of Tumour 
Necrosis Factor-α (TNF-α) and replication of HIV (166–168). In addition to suppression of TNF-α, 
thalidomide effects the generation and elaboration of a cascade of pro-inflammatory cytokines that 
activate cytotoxic T-cells even in the absence of co-stimulatory signals (169). Furthermore, Vascular 
Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) secretion and cellular 
response are suppressed by thalidomide, thus antagonizing neo-angiogenesis and altering the bone 
marrow stromal microenvironment in hematologic malignancies (170–172). In 1999, thalidomide 
was shown to be effective for the treatment of Multiple Myeloma (MM), a malignant B cell 
lymphoma (173). With respect to ENL and MM, thalidomide was approved for use by the US FDA 
in 1998 and 2006, respectively. Due to its serious teratogenicity, the prescription of thalidomide is 
strictly controlled by the System for Thalidomide Education and Prescribing Safety (STEPS) program 
(174). In South America, thalidomide is widely used for the treatment of leprosy. Sadly, many 
children have been born with severe birth defects due to poor patient understanding of the proper use 
of the drug and inconsistent contraceptive administration (175,176). 
 
2.5.1 Thalidomide teratogenicity 
The use of thalidomide during the first trimester of pregnancy led to serious embryotoxic effects; over 
10,000 children were affected worldwide. A wide spectrum of birth defects such as malformations of 
the limb, ear, eye, internal organs, and central nervous system were documented (154,155,177). Limb 
malformations were the most frequently observed defects (157,177). Thalidomide induces two types 
of limb defects: amelia and phocomelia. Amelia is complete absence of the limb, and phocomelia 
consists of limbs with a stylopod, a truncated or absent zeugopod, and a nearly intact autopod (154). 
Ear defects were also frequent; ear malformations varied from anotia to mild malformation of the 
external ear. Cleft lip and ocular anomalies such as uveal coloboma, glaucoma, microphthalmia were 
also observed, and in internal organs, the most frequent defects were kidney malformations, heart 
defects, and structural chest defects (177). The mortality rate for babies born with thalidomide-
induced defects was very high (about 30–40%). In addition, thalidomide caused an unknown number 
of miscarriages. Indeed, thalidomide induced several inoperable defects such as imperforate anus and 
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other gastrointestinal deformities, contributing significantly to early deaths (153,157,177–179). 
Facial nerve palsy was also common, and autism and mental retardation were reported even though 
the incidence was low (177) (Fig. 15). The individual type of thalidomide malformation depends on 
the time of intake. Indeed, thalidomide induced developmental defects only when taken between day 
35 to day 49 after conception and the severity of malformations correlates with the timing of exposure 
(180). 
 
 
Figure 15. Phenotype of thalidomide victims (180). 
 
Thalidomide is a derivative of glutamic acid and contains two imide rings: glutarimide and 
phthalimide with a single chiral center and is formulated as a racemic mixture of two active 
enantiomers: S (-) and R (+). The S (-) isomer was thought to work as a teratogen and the R (+) isomer 
as a sedative. However, both forms were found to be teratogenic in a rabbit model (181). Furthermore, 
both compounds rapidly interchange under physiological conditions and it is hard to isolate one form 
from the other (155,157,159). Thalidomide undergoes spontaneous non-enzymatic hydrolytic 
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breakdown into more than a dozen products under physiological conditions (155,157,159) and it is 
bio-transformed by liver cytochrome P450 (CYP450) into its hydroxylated products 
(155,157,159,182,183). It is still unclear whether the teratogenic activity is exerted by parental 
thalidomide or by its metabolites, though evidence exists that the bioactivation of thalidomide in the 
liver is not critically involved in its teratogenic action, at least in zebrafish and chicks (184–186). 
Many efforts were spent during the past 50 years trying to understand the molecular mechanisms 
underlying thalidomide teratogenicity. More than 30 hypotheses have been proposed to explain how 
thalidomide causes limb defects (187–190). To mention some, it was proposed that at the basis of 
thalidomide teratogenicity there was folic acid antagonism, DNA intercalation or the disruption of 
molecular pathways such as acetylation of macromolecules and glutamate metabolism. Among the 
most possible and reasonable causes of thalidomide embryotoxicity are thalidomide-induced 
oxidative stress and anti-angiogenic action (170,185,187,191). Nevertheless, the details of 
thalidomide molecular mechanism of action remain elusive and scientists are still looking for a 
definitive model to explain thalidomide teratogenicity. 
 
Anti-angiogenesis hypothesis 
Thalidomide is able to exert anti-angiogenic effects by suppressing VEGF and bFGF secretion and 
cellular response and thalidomide-induced anti-angiogenesis seems to be an evolutionarily conserved 
mechanism which occurs in organisms from mammals to zebrafish (170,183,185,186). The first 
report of thalidomide anti-angiogenic properties was from D’Amato et al. (170). They found that 
thalidomide inhibits bFGF-induced angiogenesis in a rabbit cornea micropocket and postulated that 
the inhibition of angiogenesis caused limb defects, since blood vessel formation is crucial for limb 
development. Similarly, Vargesson et al. (185) demonstrated that inhibition of angiogenesis by 
CPS49, a synthetic thalidomide analogue (192), precedes changes in limb morphology, cell death, 
and inhibition of Fgf8/Fgf10 in chicks (185). Therefore, they suggested that inhibition of angiogenesis 
by thalidomide induces cell death and a reduction in the expression of essential growth factors such 
as Fgf8 and Fgf10, in turn resulting in mesenchymal loss in the limb bud (Fig. 16). 
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Figure 16. Schematic model of the anti-angiogenesis hypothesis. Antiangiogenesis induced by thalidomide leads to cell 
death and downregulation of growth factors including Fgf8/Fgf10. Disruption of growth factor signaling pathways is also 
likely to be involved in cell death. The sequence of events results in mesenchymal loss and in turn limb deformities 
(157,185,193). 
 
Oxidative stress hypothesis 
In 1999, Parman et al. (191) demonstrated that thalidomide generates reactive oxygen species (ROS), 
oxidizes DNA and accumulates 8-hydroxy-20-deoxyguanosine in rabbits. Moreover, by using a spin-
trap reagent, α-phenyl-N-tertbutylnitrone (PBN), which has been shown to be effective in the in vitro 
trapping of free-radical intermediates of other teratogenic drugs, they suppressed both oxidation and 
limb defects induced by thalidomide in rabbits. Harris et al. (194) suggested that oxidative stress by 
thalidomide is likely to downregulate essential limb growth signalling. In fact, thalidomide treatment 
inhibits the expression of Fgf8 and Fgf10 and PBN pre-treatment is able to reverse this effect in 
rabbits. Fgf8 and Fgf10 have been shown to be downstream targets of Nuclear Factor-κB (NF-κB) 
(187,194). NF-κB is a redoxsensitive transcription factor whose function is affected by oxidative 
stress. Therefore, oxidative stress caused by thalidomide has been suggested to induce aberrant NF-
κB activity, which in turn attenuates Fgf8 and Fgf10 expression, resulting in limb deformities (187).  
Thalidomide treatment also leads to the upregulation of other NF-κB targets, such as Bone 
morphogenic proteins (Bmps) and Dickkopf-1 (Dkk-1). This effect was shown to be involved in 
thalidomide teratogenicity and is reversed by PBN (195). Bmps are important factors for limb 
patterning, and have been demonstrated to stabilize phosphatase and tensin homolog (PTEN) 
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proteins, which block Akt survival signalling (92,196–198). In addition, Bmps have been shown to 
inhibit Fgf signalling in mouse limb development (199). Dkk-1 is a downstream target of Bmps and 
functions as an antagonist of Wnt, which regulates cell survival and proliferation (200). Thalidomide 
blocks Wnt signalling and increases Glycogen synthase kinase-3b (Gsk3b) activity through 
upregulation of Dkk-1 (195). Stabilization of PTEN also activates Gsk3b, which in the end promotes 
the programmed cell death pathway (201) (Fig. 17). 
 
 
 
 
Figure 17. Schematic model of the oxidative stress hypothesis. Thalidomide induces ROS, and oxidative stress 
upregulates expression of Bmps through aberrant NF-κB activity. This alteration results in blocking Fgf (Fgf8/Fgf10), 
Akt, and Wnt pathways known to be important for cell survival and proliferation (154,187,193,198,202–204). 
 
 
 
2.5.2 Cereblon 
The above hypotheses seem to be both well supported by experimental data, but still do not provide 
an answer to what is the primary mediator of thalidomide teratogenicity. 
Only in 2010 Ito et al. identified the direct target of thalidomide teratogenicity (186).  
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By employing high-performance affinity ferriteglycidyl methacrylate (FG) beads, covalently 
conjugated to the carboxylic thalidomide derivative FR259625, they were able to purify from HeLa 
cell extracts a direct target of thalidomide drug. By mass spectrometry, it was possible to identify this 
protein as CEREBLON (CRBN), a protein made up of 442 amino acids, evolutionarily conserved 
from plants to humans. 
CRBN was first reported in 2004 as an autosomal recessive non-syndromic mild mental retardation 
(ARNSMR) gene. It is located at 3p25-pter and plays an important role in central nervous system 
development, being involved in memory and learning. The nomenclature of CRBN is based on its 
putative role in cerebral development and on the presence at the N-terminus of a large (237-
aminoacids) highly conserved ATP-dependent Lon protease domain. However, whether this protein 
possesses ATP-dependent Lon protease activity or not has not been convincingly proved. 
Furthermore, CRBN protein sequence contains 11 casein kinase II phosphorylation sites, 4 protein 
kinase C phosphorylation sites, 1 N-linked glycosylation site and 2 myristoylation sites (205,206). 
CRBN is highly expressed in human brain (206,207) but it is also widely expressed in testis, spleen, 
prostate, liver, pancreas, placenta, kidney, lung, skeletal muscle, ovary, small intestine, peripheral 
blood leukocyte, colon, and retina (207–211). At a subcellular level, CRBN is located in cytoplasm, 
nucleus and peripheral membrane (186,208–212). The discovery by Ito et al. that CRBN directly 
interacts with damaged DNA binding protein 1 (DDB1), that it co-precipitates with all the 
components of  the Cullin 4 (Cul4)-based E3 ubiquitin protein ligase complex and that it has intrinsic 
ubiquitination activity indicates that CRBN is a subunit of this E3 ubiquitin ligase complex. In the 
Cul4-based complex, CRBN functions as a substrate receptor, whilst regulator of cullins 1 (Roc1) 
and Cul4 form the catalytic core, and DDB1 works as an adaptor between Cul4 and the substrate 
receptor (186). Cul4-based E3 ubiquitin ligases have been shown to be important for DNA repair 
(213–219), DNA replication (220–223), transcription (224) and development (186). Thalidomide is 
able to inhibit CRBN autoubiquitination in vitro, suggesting that thalidomide is an inhibitor of its E3 
ubiquitin ligase activity (186). 
The CRBN Y384A/W386A (CRBNYW/AA) double point mutant (Fig. 18), unable to bind to 
thalidomide, does not display loss of autoubiquitination activity upon drug treatment, suggesting that 
thalidomide inhibits E3 function of the CRBN-containing complex by directly binding to CRBN 
(186). 
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Figure 18. Evolutionary conservation of CRBN. Amino acid sequences of CRBN orthologs from six species are aligned. 
Bold letters indicate amino acids that are fully conserved among these species. Asterisks indicate amino acids that are 
critical for thalidomide binding (186). 
 
In vivo studies on zebrafish embryos revealed that the microinjection in 2 cells-stage embryos of the 
mRNA encoding for CRBN Y384A/W386A, rescues the defects otherwise induced by thalidomide in 
ear and pectoral fin development (186) (Fig. 19).  
 
 
Figure 19. Expression of a drug binding-deficient form of CRBN suppresses thalidomide-induced teratogenicity in 
zebrafish. Dorsal views of pectoral fins of 72-hpf embryos. Fins are indicated by arrowheads. Uninjected control embryos 
in the left-most panel. Embryos injected with WT zcrbn mRNA in the middle panel. Embryos injected with WT zcrbnYW/AA 
mRNA in the right-most panel. After injection, embryos were allowed to develop in the presence (above) or absence 
(below) of thalidomide (186). 
 
 
Collectively, all these pieces of evidence suggest that thalidomide exerts its teratogenic effects by 
binding to CRBN and inhibiting its function, indicating that CRBN is a primary target of thalidomide 
teratogenicity (186). However, the ubiquitously expressed CRBN protein cannot account alone for 
the tissue-specificity of thalidomide teratogenicity, indicating that CRBN is necessary but not 
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sufficient for thalidomide teratogenicity. Other molecules, perhaps downstream to CRBN E3 
ubiquitin ligase activity, are likely to contribute to the effects of the drug and may define the tissue 
specificity of thalidomide teratogenicity. One such molecule might be fgf8 whose expression pattern 
is tissue-specific and results to be downregulated in zebrafish embryos upon thalidomide treatment. 
Ito et al. speculate that thalidomide might initiate teratogenic effects by inhibiting CRBN E3 ubiquitin 
ligase function, thus leading to the accumulation of unknown substrates that might be negative 
regulators of essential factors for correct limb/fin development, such as fgf8 (186) (Fig. 20).  
 
 
 
Figure 20. Schematic model of the molecular mechanisms of thalidomide teratogenicity from a CRBN-centric perspective. Thalidomide 
binds directly to CRBN and inhibits its E3 ubiquitin ligase activity. This inhibition results in aberrant accumulation of substrates (unknown), 
which in turn causes developmental defects such as limb deformities. Thalidomide-induced downregulation of Fgfs (Fgf8/Fgf10) might 
mediate the teratogenic effects of thalidomide-CRBN binding (186,193). 
 
 
2.5.3 Species-specificity of thalidomide teratogenicity 
Apparently, the first pharmacological trials performed on rodents did not reveal any remarkable toxic 
effect of the drug, which was therefore launched on the market in 1957. This tragic mistake was 
probably related to the characteristic species-specificity of thalidomide teratogenicity. Thalidomide 
induces limb/fin deformities in humans, monkeys, rabbits, chicks, and zebrafish (Danio rerio) 
(154,186). 
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In particular, amelia only occurs in chicks, whereas both amelia and phocomelia occur in monkeys. 
In zebrafish, thalidomide induces shortening along the proximo-distal axis of the pectoral fins, which 
are homolog structures to tetrapod limbs (see above) (93). On the contrary, rodents are resistant to 
limb deformities induced by thalidomide (154,155,157–159), even when administered at doses of up 
to 4,000 mg/kg (225). However, several reports have demonstrated the effects of thalidomide (e.g., 
anti-angiogenic effect) in cell lines and tissues from mice and rats (157,226,227). There is no clear 
explanation for rodents resistance. Mouse/rat CRBN is 95% homologous to human CRBN and has 
been shown to bind thalidomide (186). Hence, CRBN is unlikely to direct the species-specificity of 
thalidomide effects, but several other hypotheses have been proposed to explain why rodents are 
resistant to the teratogenic effects of thalidomide. One possibility is that differences in the 
pharmacokinetics of thalidomide metabolism among different species may reflect the diverse 
sensitivity. Indeed, the plasma elimination half-life of orally administered thalidomide is significantly 
shorter in mice (0.5 h) than in rabbits (2.2 h) and humans (7.3 h) (228). Thalidomide is rapidly 
hydrolyzed or metabolized into over a dozen products in vitro and in vivo, and many of the breakdown 
products are non-teratogenic (185); a more efficient thalidomide metabolism might confer to rodents 
resistance to the teratogenic effects of the drug. On the other side, if the breakdown or bioactivation 
of thalidomide is required for the induction of its embryotoxic effects, then again differences in the 
metabolism of the drug will explain the species-specificity of thalidomide teratogenicity. However, 
evidence exists that the bioactivation of thalidomide in the liver is not critically involved in its 
teratogenic action. In zebrafish, developmental defects were observed very early in development 
(around 30 hpf), when the liver is not functional yet (184). In chicks, thalidomide applied directly to 
one of the forelimb buds causes specific defects in the thalidomide-treated limb, but not in the other 
limb (185,186). Another chance is that thalidomide might be less efficient in causing ROS formation 
in the rodents. In support of this, the glutathione-dependent antioxidant response is stronger in mice 
and rats than in humans (229). Finally, interspecies differences in gestational development may result 
in different developmental toxic manifestations after exposure to thalidomide (230).  
 
2.5.4 Immunomodulatory drugs and thalidomide analogues 
The term IMiD (immunomodulatory drugs) refers to IMiDs licensed by Celgene Corporation 
(Summit, NJ, USA) for the treatment of several inflammatory and neoplastic diseases (158). The 
IMiDs were initially defined by their capacity to inhibit tumor necrosis factor (TNF)-α secretion 
(231). The second generation IMiDs CC-5013 (Revlimid, IMiD3, hereafter lenalidomide) and CC-
4047 (Actimid, IMiD1, hereafter pomalidomide), are amino-phthaloyl-substituted thalidomide 
analogues developed on the basis of augmented TNF-α inhibition (232,233) (Fig. 21). 
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Figure 21. Chemical structures of the ‘IMiDs’, thalidomide and its amino-phthaloyl-substituted analogues (231). 
 
 
Thalidomide, pomalidomide and lenalidomide display a wide range of overlapping and pleiotropic 
biological activities, including anti-angiogenic and teratogenic properties and multiple effects on the 
immune system, such as enhanced production of the cytokine interleukin-2 (IL-2) (which spurs T cell 
production), inhibition of the cytokine tumor necrosis factor (TNF), and the stimulation of natural 
killer cells (234). Importantly, IMiDs possess also anti-cancer activity with selectivity for molecularly 
defined subgroups of hematological malignancies, such as MM and other specifically mature B-cell 
neoplasms (231) (Fig. 22).  
 
 
 
Figure 22. The pleotropic effects of thalidomide analogues. 
Part I 
33 
 
MM is a malignancy of immunoglobulin producing plasma cells associated with systemic toxicities 
including renal failure, anemia, immunoparesis and destructive skeletal lesions (235). 
Interestingly, low amounts of CRBN in multiple myeloma cells correlate with clinical drug resistance 
and poor survival outcomes (236), whilst high CRBN levels in myeloma cells are associated with 
increased responsiveness to IMiDs (236,237). Lu et al. and Krönke et al. demonstrated that the zinc 
finger–containing transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) are selectively bound by 
CRBN. IKZF1 and IKZF3 are transcriptional regulators of B and T cell development (238,239). After 
direct binding, IMiDs activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and 
degradation of IKZF1 and IKZF3. IMiDs-mediated loss of these two transcription factors is toxic for 
MM cells, thus explaining the molecular mechanism of IMiDs clinical effect on MM (240–242) (Fig. 
23). 
 
 
Figure 23. The small-molecule drugs thalidomide, lenalidomide and pomalidomide bind to the protein cereblon (CRBN), 
which activates the enzymatic activity of the CRBN E3 ubiquitin ligase complex. The transcription factors Ikaros (IKZF1) 
and Aiolos (IKZF3) are modified with ubiquitin (Ub) molecules, targeting them for proteolysis. This alters the function 
of T cells and B cells, with a toxic outcome for MM cells. 
 
 
It is not clear how IMiDs binding to CRBN can promote the degradation of IKZF1 and IKZF3. It has 
been proposed that the underlying mechanism might conceptually resemble the auxin-induced 
degradation of members of the Aux/IAA repressor family by the ligase TIR1 (243). The CRL4CRBN 
architecture supports ubiquitination in its vicinity, a property that is exploited by viral proteins in 
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recruiting cellular targets for degradation by CRL4s (244). Small molecules such as thalidomide and 
its derivatives may mimic this behaviour, bringing novel substrates such as IKZF1 and IKZF3 in the 
vicinity of CRL4CRBN complex, thus promoting their degradation (245). 
Studies on the crystallized structure of a chimaeric complex of human DDB1 and Gallus gallus 
(chicken) CRBN bound to thalidomide, lenalidomide and pomalidomide revealed that they bind to 
CRBN at the canonical substrate-binding site. Thus, IMiDs, by binding to CRBN, simultaneously 
confer to the E3 complex new substrate specificity while interfering with the recruitment of 
endogenous substrates (such as MEIS2) to CRL4CRBN, as they occupy the binding site (245) (Fig. 
24). 
 
 
 
Figure 24. Molecular model of IMiDs function. (a) Thalidomide binds to CRBN at the canonical substrate-binding site. 
(b) The potent anti-myeloma drug thalidomide and its derivatives lenalidomide and pomalidomide occupy the same site 
but with different solvent-exposed moieties. (c) Binding of the endogenous substrate MEIS2 and the IMiDs to this site is 
mutually exclusive. (d) Direct interaction of lenalidomide or pomalidomide with IKAROS transcription factors (IKZF1 
and IKZF3).  
 
Overall, these observations suggest that IMiDs are not simply CRBN antagonists, as proposed by Ito 
et al. in 2010 (186), instead, they seem to more generally alter the substrate specificity of CRBN to 
include proteins important in myeloma (240,241). 
To explain the complex, pleiotropic effects of thalidomide and its analogues, it is therefore necessary 
to consider both their inhibitory function on CRBN activity on its endogenous substrates and their 
ability to induce a CRBN gain of function towards de novo substrates. 
  
Part I 
35 
 
2.6 Regulatory post-translational modifications of the p53 family 
members 
Post-translational modifications are covalent processing events that change the properties of a protein 
by either proteolytic cleavage or by the addition of a modifying group to one or more aminoacids. 
These modifications can diversify proteins function and regulate their availability. Acetylation, 
sumoylation, phosphorylation and ubiquitination can affect the half-life, the specificity and efficiency 
of protein-protein interactions and overall modulate the transcriptional activity of the p53 family 
members (Fig. 25). In particular, to maintain p63 key role in the regulation of correct limb 
development, it is not only necessary the integrity of its DBD but also a tight control of the 
mechanisms that control its stability and activity.  
2.6.1 Acetylation 
Acetylation is a reversible process by which an acetyl group is covalently linked to the ε amino-group 
of lysine residues of a target protein. Acetylation was first discovered on histones; acetylation of 
internal lysine residues of core histone has been found associated with transcriptional activation in 
eukaryotes. However, acetylation process does not involve only histone proteins.  
Acetylation and deacetylation have been described as fundamental mechanisms in the regulation of 
p53 activation and stability (110–117). 
p53 is acetylated by Tip60/hMOF protein on lysine 120 (117) and by p300 acetyl-transferase on its 
C-terminus and on lysine 164 (K164) (110). Loss of acetylation at all these major sites completely 
abolishes p53 ability to activate p21 and suppresses cell growth (110). Moreover, acetylation blocks 
the interaction of p53 with its repressors MDM2 and MDMX and this event directly results in p53 
activation (116). Interestingly, K164 in p53 corresponds to lysine 193 (K193) in p63, which is 
mutated to glutamic acid (K193E) in patients affected by SHFM4 (Fig. 26).  
 
 
Figure 26. Alignment of the K164 flanking region of the human p53 protein with those of the murine protein and of 
human p63 and p73. The conserved lysine residue is marked in bold; h: human; m: mouse (110). 
 
Acetylation has been largely demonstrated to be essential also for p73 regulation. p73 acetylation 
following DNA damage potentiates its apoptotic function by increasing its ability to activate the 
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transcription of proapoptotic target genes. Indeed, p73α is acetylated in a c-Abl-dependent manner 
by p300 in response to apoptotic concentrations of the DNA-damaging drug doxorubucin on three 
conserved lysines at positions 321, 327, and 331 and a non-acetylatable p73 mutant is impaired in the 
activation of the apoptotic gene p53AIP1 (118,119). 
 
2.6.2 Phosphorylation 
Phosphorylation is the addition of a phosphate group to a serine, tyrosine or threonine residue which 
can alter the conformation and function of a protein by locally altering its charge and hydrophobicity.  
Multiple sites of phoshphorylation have been described in p53 protein and specific phosphorylation 
events can regulate specific biochemical and/or biological functions of p53. 
The N-terminus of p53 is highly phosphorylated and is the target for a range of different protein 
kinases, each of which is activated through pathways responding to cellular stresses (such as DNA 
damage) or changes in growth status (120). The N-terminal 15 amino acids of p53 contain the most 
highly phosphorylated sites in the protein (121) which are substrates for several kinases such as DNA-
activated Protein Kinase (DNA-PK) (122–124) and Casein Kinase 1α (CK1α) (125). The proline-rich 
and transactivation domains of p53 are also targets for members of the Mitogen-Activated Protein 
(MAP) kinase family (126,127) and of the related Stress-Activated Protein (SAP) kinase family (128), 
respectively. Moreover, three phosphorylation events take place at different locations within the C-
terminus of p53, by Cyclin-Dependent protein Kinases (CDKs) (129,130), Protein Kinase C (PKC) 
(131–135) and Protein Pinase CK2 (136–140). Each of these modifications leads to stimulation of 
the sequence-specific DNA-binding function of the protein. 
A tight regulation of protein expression and function is achieved through a complex cross-talk among 
different post-translational modification events. For instance, the above mentioned acetylation of p73 
occurs after a phosphorylation events. c-Abl induces the phosphorylation of p73 on threonine residues 
adjacent to prolines, and this modification, together with a second phosphorylation mediated by p38 
MAPK (141), in turn favors binding of PIN-1 prolyl isomerase, promoting a conformational change 
that stimulates p300-mediated acetylation of p73 upon genotoxic stress (142–145). 
Also ΔNp63α is directly phosphorylated by c-Abl and this modification promotes increased binding 
to YAP, resulting in p63 increased stability. c-Abl phosphorylates p63 on multiple sites (Y55, Y137F 
and Y308) and the combined mutant construct with the three tyrosines mutated to phenylalanine 
displays greatly diminished binding to YAP compared with wild-type ΔNp63α (146). 
In a similar way, Dlx3 tightly controls p63 isoforms availability during epithelial stratification upon 
Raf1 kinase-mediated p63 phosphorylation on serine 383 and threonine 397 residues (24) and PIN-1 
regulates p63 protein levels in a phosphorylation-dependent manner (51). 
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2.6.3 Ubiquitination 
Very well established is the cross-talk between phosphorylation and ubiquitination of p53 family 
members. Ubiquitination is an enzymatic process in which an ubiquitin protein is attached to a 
substrate protein. Usually, this process is divided into three steps: activation, conjugation and ligation, 
performed respectively by an ubiquitin-activating enzyme (E1), an ubiquitin-conjugating enzyme 
(E2) and an ubiquitin ligase (E3). In the last step, the glycine 76 residue of ubiquitin is covalently 
linked to a lysine of the substrate protein. Depending on the number of ubiquitin proteins attached to 
the substrate protein, ubiquitination can lead to different results. Mono-ubiquitination can modify 
protein localization, affect protein activity or promote the interaction with other proteins. On the 
contrary, poly-ubiquitination is usually associated to the proteasome targeting of the protein and 
consequently to its degradation.  
The principal negative regulator of p53 is the E3 ubiquitin ligase MDM2 and phosphorylation of p53 
disturbs the interaction with MDM2 thus leading to p53 accumulation and activation (147). Unlike 
p53, p73 and p63 bind to, but are not degraded by MDM2 (148,149). Both p73 and p63 levels are 
controlled by Itch, a Hect ubiquitin-protein ligase. Itch binds and ubiquitinates p73 and p63 but not 
p53, resulting in their rapid proteasome-dependent degradation (150–152). However, also MDM2 
contributes to the regulation of p63 protein levels, even though it does not directly ubiquitinates the 
protein. In fact, upon DNA damage or keratynocytes differentiation, MDM2 cooperates with the 
FBWX7 E3-ubiquitin ligase to induce proteasome-mediated degradation of ΔNp63α. MDM2 
promotes ΔNp63α translocation to the cytoplasm, where it is targeted for degradation by FBWX7-
mediated ubiquitination. Efficient degradation of ΔNp63α by FBWX7 requires GSK3 kinase activity, 
which phosphorylates ΔNp63α on residue serine 383 (149). 
  
 
 
 
Figure 25. Sites of post-translational modifications on p53. Schematic representation of the 393 amino acid domain 
structure of human p53 showing the sites of post-translational modification including phosphorylation, acetylation, 
ubiquitination, methylation, neddylation, and sumoylation. Abbreviations: N-terminal transactivation domain (TAD); 
proline-rich domain (PRD); tetramerisation domain (TET); C-terminal regulatory domain (REG); arginine (R); lysine 
(K); serine (S); threonine (T). 
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3. Aim of the work 
The p63 transcription factor, homolog to the p53 tumor suppressor, plays a pivotal role in limb, 
epithelial and cranio-facial development. The focus of our laboratory is to investigate the complex 
networks centered on p63 that govern limb and epithelia development. In particular, we are interested 
in the upstream signalling pathways that control p63 stability and activity in physiological and 
pathological conditions. 
As mentioned before, the p53 family members are largely regulated by a huge numbers of post-
translational modifications. Acetylation, sumoylation, phosphorylation and ubiquitination affect p63 
stability and function and overall modulate the transcriptional activity of the protein. A perturbation 
of these regulative mechanisms can result in the alteration of p63 role in limb and epithelia 
development, in the end resulting in limb malformations and defective formation of the skin. Thus, 
investigating the upstream pathways and post-translational modifications that control p63 function is 
crucial to understand the genetic and molecular causes of those pathological conditions involving 
p63. 
 
Dominant mutations in the p63 gene give rise to several human congenital syndromes like 
Ectrodactyly-Ectodermal displasia-Cleft lip/palate (EEC), Ankyloblepharon-Ectodermal displasia-
Clefting (AEC), Limb-Mammary Syndrome (LMS) and Split-Hand/Footh Malformation (SHFM) 
type 4 (13,246). Disease causing mutations can occur in the DNA Binding Domain (DBD) but can 
also reside in target sites for post-translational modifications. In 2008 was identified in the sequence 
of p53 protein a residue, lysine 164, which can be acetylated by acetyl-transferase CBP/p300 (110). 
The consideration that this lysine is conserved in p63 and that it corresponds to lysine 193 of ΔNp63α, 
which is mutated into glutamic acid (K193E) in patients affected by SHFM4, prompted us to verify 
whether ΔNp63α is acetylated on this residue and the relevance of this post-translational modification 
in limb development. 
 
At the same time, the observation that the limb defects presented by EEC, LMS, ADULT and SHFM4 
patients show a striking resemblance with the malformations induced by the teratogenic drug 
thalidomide prompted us to verify whether thalidomide could affect p63 function and/or stability. It 
has occurred that EEC patients have been wrongly referred as possible victims of thalidomide (189). 
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Indeed, our data indicate that ΔNp63α is a target of thalidomide teratogenicity and reveal that 
thalidomide is able to downregulate ΔNp63α protein. Furthermore, we set forth to investigate the 
upstream pathway through which thalidomide exerts its modulation of ΔNp63α levels and the post-
translational modifications involved in this process. Finally, using zebrafish as a model system, we 
verified the in vivo relevance of ΔNp63α downregulation in the onset of thalidomide-induced 
malformations.  
Thalidomide is now used for treatment of multiple myeloma and leprosy (160,173): a better 
understanding of its mechanism of action might pave the way for the design of related compounds 
with equal therapeutic properties but devoid of teratogenic activity. 
Moreover, ΔNp63α was shown to be involved in several types of cancer such as Squamous Cell 
Carcinoma (SCC), pediatric neuroblastoma and osteosarcoma (247,248). The study of thalidomide 
ability to modulate ΔNp63α levels might also have therapeutic implications for those neoplastic 
conditions in which ΔNp63α is overexpressed. 
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4. Main results 
 
4.1 FGF8, c-Abl and p300 participate in a pathway that controls 
stability and function of the ΔNp63α protein 
 
Acetylation of p53 on lysine 164 (K164) by p300 is enhanced in response to DNA damage and 
correlates with p53 stabilization and activation (110). K164 in p53, corresponds to lysine 193 (K193) 
in ΔNp63α, which is mutated into glutamic acid (K193E) in SHFM4 (49,249).  
Western blot analysis revealed that the p300 acetyl-transferase physically interacts with ΔNp63α and 
catalyzes its acetylation on K193. Indeed, overexpression of p300 stabilizes ΔNp63α in HaCaT cells 
and acetylation assay revealed that a synthetic p63 peptide centered on K193 is acetylated in vitro, 
whilst the levels of acetylation of the p63-K193R mutant were reduced.  
Interestingly, qPCR analyses in U2OS cells stably transfected with either the wild-type ΔNp63α or 
the ΔNp63α-K193E revealed that the ΔNp63α-K193E mutant displays an altered transactivation 
activity on ΔNp63α target genes involved in development and apoptosis, while it behaves like the 
wild-type ΔNp63α on p53, involved in cell cycle regulation. Similarly, ChIP experiments showed 
that  ΔNp63α-K193E mutant is not efficiently recruited on the Responsive Elements (RE) of genes 
relevant for developmental and apoptotic processes while it is normally recruited on RE of the p53 
gene.  
Moreover, Fibroblast Growth Factor-8 (FGF8), a morphogenetic signalling molecule essential for 
embryonic limb development, displayed the ability to stabilize ΔNp63α protein by increasing the 
binding of ΔNp63α to the tyrosine kinase c-Abl. HaCaT cells treated with FGF8 displayed a great 
increase in ΔNp63α-c-Abl interaction and also in the levels of ΔNp63α acetylation. Furthermore, co-
immunoprecipitation experiments of p300 with wild-type ΔNp63α or with the ΔNp63α-3Y mutant, 
with the three tyrosines known to be phopshorylated by c-Abl mutated into phenylalanine (146,250), 
revealed that ΔNp63α-3Y mutant displays a drastically reduced interaction with p300. FGF8 appeared 
also to activate ΔNp63α transactivation functions and when we inhibited c-Abl kinase activity, 
ΔNp63α was unable to transactivate its target genes, even in the presence of FGF8.  
These results link FGF8, c-Abl and p300 in a regulatory pathway that controls ΔNp63α protein 
stability and transcriptional activity. Notably, the natural mutant ΔNp63α-K193E, associated to 
SHFM4, cannot be acetylated by this pathway. Hence, our data, indicating that K193E mutation is 
likely to result in aberrant limb development via the combined action of altered protein stability and 
altered promoter occupancy, shed new light on the molecular mechanism that could be at the bases 
of the SHFM4 pathogenesis. 
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4.2 Np63 is a molecular target of thalidomide teratogenicity 
 
The phenotypic similarity between thalidomide-induced malformations and those due to mutations in 
p63 gene prompted us to determine whether p63 could be a molecular target of the drug. Western blot 
analysis performed on lysates from human keratinocyte (HaCaT) cells treated with thalidomide 
revealed that the drug induces a reduction of Np63 protein levels, which is not accompanied by a 
reduction of Np63 transcript levels. This effects was blocked when the cells were treated with the 
proteasome inhibitor MG132, suggesting that thalidomide induces a proteasome-mediated 
degradation of Np63. The transfection of human osteosarcoma cells (U2OS), which do not 
endogenously express p63, with either ΔNp63α, ΔNp63β or ΔNp63γ isoforms revealed that 
thalidomide treatment efficiently leads to a downregulation of ΔNp63α and ΔNp63β isoforms but 
does not alter ΔNp63γ protein levels. Moreover, thalidomide acts specifically on p63 transcription 
factor, since the protein levels of NF-Y and p53 transcription factors were not altered by the treatment. 
By using a series of deletion mutants, we were able to identify the protein region responsible for 
mediating thalidomide effect on p63. In this region are present two residues indispensable for 
thalidomide-induced degradation of Np63: serine 383 and threonine 397. These two residues are 
centered on two predicted phosphodegrons for the FBWX7 E3 ubiquitin ligase, which promotes the 
degradation of ΔNp63α and ΔNp63β isoforms upon DNA damage or keratinocytes differentiation. 
FBWX7 binds to its targets in a phosphorylation-dependent manner and most of its known substrates 
are phosphorylated by Glycogen Synthase Kinase 3 (GSK3) (149). The silencing of endogenous 
FBWX7 in HaCaT cells abolished ΔNp63α protein modulation upon thalidomide treatment as well as 
the inhibition of GSK3 kinase activity with the specific inhibitor SB216763, indicating that the 
thalidomide-induced downregulation of ΔNp63α requires the activity of FBWX7 E3 ubiquitin ligase 
and GSK3 kinase.  
In 2010 Ito et al. demonstrated that thalidomide treatment induces fin defects in developing zebrafish 
embryos (186). Western blot analysis performed on total extracts from zebrafish embryos revealed 
that thalidomide is able to induce a downregulation of p63 also in vivo. In zebrafish, p63 is an 
important regulator of correct fin outgrowth and it is upstream to dlx5 in the control of fin 
development (11,12,52). Thalidomide treatment results in a downregulation of dlx5 protein in 
zebrafish embryos, indicating that thalidomide-induced downregulation of p63 results in a general 
impairment of the downstream fin developmental pathway. 
Most importantly, the microinjection of zp63-mRNA into embryos, subsequently treated with 
thalidomide, was able to rescue the thalidomide-induced defects in pectoral fin development, strongly 
suggesting that p63 downregulation is at least in part responsible for the onset of the malformations 
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induced by the drug. Finally, Real Time qPCR performed on total RNA extracts from these embryos 
revealed that the microinjection of zp63-mRNA is able to restore the expression levels of tbx5a and 
prrx1a, two genes essential for correct fin development (251–253), otherwise altered by thalidomide 
treament. Thus, the restoration of p63 levels can rescue thalidomide-induced alterations in fin 
development not only at a phenotypical but also at a molecular level. 
 
4.3 CRBN is a negative regulator of Np63 protein 
 
CRBN, which is substrate receptor in E3 ubiquitin ligase complex CRL4, is the only direct target of 
thalidomide identified so far (186). We were interested in verifying whether ΔNp63α could be 
downstream to CRBN in the teratogenic cascade initiated by thalidomide. 
Western blot analysis revealed that silencing of endogenous CRBN results in an upregulation of 
ΔNp63α protein levels in U2OS cells. On the contrary, the overexpression of CRBN led to a reduction 
of transfected ΔNp63α protein and this effect was blocked when the cells were treated with the 
proteasome inhibitor MG132, indicating that CRBN is a negative regulator on Np63 protein. 
The transfection of  U2OS cells with either ΔNp63α, ΔNp63β or ΔNp63γ isoforms revealed that 
CRBN overexpression leads specifically to a downregulation of ΔNp63α and ΔNp63β, whilst does 
not alter the levels of ΔNp63γ and p53, in a similar way as thalidomide treatment.  
Crbn appears to function as a negative regulator of p63 also in vivo in zebrafish embryos, where its 
knockdown through the microinjection of a specific crbn-Morpholino leads to an increase of p63 
protein levels.  
CRBN is highly conserved from fish to mammals and can hardly account alone for the species-
specificity of thalidomide teratogenicity. It is possible that other molecules, perhaps downstream 
targets of CRBN, may define the specificity of thalidomide teratogenicity. The overexpression of 
either human or mouse CRBN in a murine context (mouse embryonic fibroblast NIH3T3 cells) 
revealed that mouse CRBN is significantly less efficient in interacting with ΔNp63α and promoting 
its downregulation, compared to the human orthologous. Should ΔNp63α be a downstream target of 
CRBN in thalidomide teratogenic cascade, the differential sensitivity of ΔNp63α to CRBN 
orthologues from different species might provide a hint into the species-specificity of thalidomide 
teratogenicity.  
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5. Future perspectives 
The results presented in this thesis indicate that thalidomide treatment induces a reduction of ΔNp63α 
protein levels and a downregulation of its target dlx5 not only in vitro but also in vivo and that this 
effect is, at least in part, at the basis of the phenotypical defects that we observed in the pectoral fins 
of the treated zebrafish embryos. In future, we plan to analyse the effects of thalidomide treatment in 
embryos microinjected with either zΔNp63-mRNA or control-mRNA on the expression levels of 
other p63 target genes (Ikka, Dlx5, Dlx6, Perp, Redd1) (27,28,38,47,50) and on other genes known 
to be involved in zebrafish fin fold formation, such as fgf8 and shha (95–97).  
The mechanism through which thalidomide leads to a reduction of ΔNp63α protein levels is not 
completely clear but it is possible that the thalidomide primary target CRBN is involved in this 
process. The preliminary data I collected up to now indicate that CRBN is a negative regulator of 
ΔNp63α protein. In fact, CRBN overexpression in U2OS cells results in a decrease of transfected 
ΔNp63α protein levels, whilst CRBN knockdown results in an upregulation of ΔNp63α protein both 
in U2OS cells and in zebrafish embryos.  
In future, I plan to verify if CRBN is involved in thalidomide-induced degradation of ΔNp63α by 
analysing the effects of thalidomide treatment on ΔNp63α protein levels in cells where CRBN has 
been silenced or overexpressed. Moreover, I plan to verify whether CRBN directly ubiquitinates 
ΔNp63α or it acts on a regulator of ΔNp63α stability. Finally, we previously demonstrated that 
thalidomide promotes p63 degradation via FBWX7 ubiquitin ligase activity. Should CRBN 
contribute to thalidomide-induced ΔNp63α downregulation, to fully appreciate the model it is 
necessary to understand whether CRBN interacts with FBWX7 or it functions through an independent 
pathway.  
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Supplementary material 
 
Figure S1. WB analysis of U2OS cell extracts transfected with Np63 expression vector (30 
ng) and then treated with increasing amounts of Trichostatin (TSA) (5 ng/ml and 10 ng/ml) for 
5 hours or Valproic acid (VPA) (0,5 mM and 1 mM) for 3 hours. 
 
Figure S2. WB analysis of HaCaT whole cell extracts transiently co-transfected with shp300 
and shLuc expression vectors (80 ng). 48 hours after transfection protein half-life was 
measured by treating cells with 10 μg/ml of Cycloheximide (CHX). 
 
Figure S3. Alignment of the human and mouse p53 protein region flanking K164 with human 
p63 and p73 sequences. The conserved lysine is marked in bold (h: human; m: mouse) 
 
Figure S4. WB analysis of U2OS whole cell extracts transiently transfected with Np63 or 
Np63-3Y expression vectors (30 ng) and treated with FGF8 (0.5 ng/ml) for 2 hours. 
 
Figure S5. WB analysis of U2OS whole cell extracts transiently co-transfected with Np63 
or Np63-3Y expression vectors (30 ng) and increasing amount of p300 (10 and 20 ng) 
encoding plasmids. 
 
Figure S6.  Luciferase assay performed on U2OS cells transiently co-transfected with the -
1200 bp DLX5 promoter (200 ng) and Np63. 24 hours after transfection U2OS cells were 
treated with FGF8 (0,5 ng/ml) for 2 hours, or Imatinib (5 μM) alone for 2 hours and 30 minutes, 
or pretreated with Imatinib for 30 minutes then followed by FGF8 treatment for 2 hours. 
Standard deviations are indicated. 
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Abstract 
The transcription factor p63 plays a key role in limb, epithelial and cranio-facial development and 
p63 mutations can cause severe limb malformations; in some cases, the clinical features of p63 
patients were similar to thalidomide-induced malformations. Thalidomide was largely prescribed 
against morning sickness in the early 1950s to pregnant women, causing a worldwide epidemic of 
newborn defects. Because of thalidomide potent teratogenic effects, the drug was withdrawn from 
the market but its use has been recently approved in the treatment of leprosy and multiple myeloma. 
It is therefore important to describe the molecular mechanism at the basis of thalidomide 
teratogenicity. Our data indicate that ΔNp63α is a new molecular target of thalidomide teratogenicity. 
Here we report that thalidomide induces proteasome-mediated degradation of ΔNp63α via the activity 
of GSK3 kinase and FBWX7 E3 ubiquitin ligase. Moreover, we show that, in zebrafish embryos, the 
restoration of normal levels of p63 is sufficient and necessary to readjust the general perturbation 
induced by thalidomide in fin development. Our results, by demonstrating that the downregulation of 
ΔNp63α protein levels is at the basis of thalidomide-induced pectoral fin malformations, provide a 
fundamental missing piece in the description of the molecular mechanisms of thalidomide 
teratogenicity. 
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Introduction 
The p63 transcription factor, homolog to the p53 tumor suppressor, plays a pivotal role in limb, 
epithelial and cranio-facial development (1,2). A tight regulation of p63 activity and stability is 
indispensable to maintain its correct function during development. This control is achieved through 
a wide spectrum of post-translational modifications that can modulate p63 half-life, localization and 
interactions under specific stimuli (3–6). Indeed, we previously reported that, upon DNA damage or 
keratinocytes differentiation, ΔNp63α can be ubiquitinated and targeted for degradation by the FBW7 
E3-ubiquitin ligase. Efficient degradation of ΔNp63α by FBWX7 requires GSK3 kinase activity, 
which phosphorylates p63 on serine 383 (S383) residue (7). 
The p63 gene encodes for at least ten protein isoforms, which differ in their amino and carboxy-
terminal regions as a consequence of alternative transcription start site and alternative splicing, 
respectively (8,9), with ΔNp63α being the most expressed isoform in the embryonic ectoderm. 
ΔNp63α is at the centre of a complex molecular network that controls Apical Ectodermal Ridge 
(AER) function and maintenance via transcriptional regulation of  the DLX5 and DLX6 genes that are 
in turn regulators of the essential morphogenetic factor FGF8 (10–12). Accordingly, p63 homozygous 
mutant mice show severe defects affecting their limbs, skin and craniofacial skeleton. In p63-/- new-
born animals, the hindlimbs are absent whereas the forelimbs are severely truncated in their distal 
segment (1,2). The limb defects observed in p63-/- mice are highly reminiscent of the phenotype of 
patients affected by conditions due to specific mutations in p63 gene, such as Ectrodactyly-
Ectodermal dysplasia-Clefting (EEC) syndrome (MIM 604292), Limb-Mammary Syndrome (LMS 
[MIM 603543]), Acro-Dermato-Ungual Lacrimal-Tooth (ADULT) syndrome (MIM 103285), and 
nonsyndromic Split-Hand/Foot Malformation (SHFM) type 4 (13,14). 
The limb defects presented by EEC, LMS, ADULT and SHFM4 patients show a striking resemblance 
with the malformations induced by the teratogenic drug thalidomide. It has occurred that EEC patients 
have been wrongly referred as possible victims of thalidomide (15). In 1950s, prescription of the 
sedative drug thalidomide (α-(N-phthalimido)glutarimide)  caused a worldwide epidemic of multiple 
birth defects and it was soon withdrawn from the market. The uptake of thalidomide by pregnant 
women during their first trimester of gestation caused in the newborns multiple defects such as limb, 
ear, cardiac, and gastrointestinal malformations. The limb malformations, known as phocomelia and 
amelia, are characterized, respectively, by severe shortening or complete absence of legs and/or arms 
(16–18). The fact that, on the contrary, no remarkable toxicity was observed when the drug was tested 
on rodents is probably due to the species-specificity of thalidomide teratogenicity; the drug is able to 
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induce limb/fin deformities in humans, monkeys, rabbits, chicks, and zebrafish (Danio rerio) but not 
in rats and mice (19).  
In 1965 there was a renewal of the interest in thalidomide, as it was shown to have immunomodulatory 
and anti-inflammatory properties in patients with Erythema Nodosum Leprosum (ENL), a painful 
complication of leprosy (20). Thalidomide was also found to inhibit the basic Fibroblast Growth 
Factor (bFGF)-induced formation of new blood vessels (21) and the production of vascular 
endothelial growth factor (22). These findings prompted clinical trials exploring thalidomide use for 
anti-angiogenic cancer therapy. The efficacy of thalidomide and its derivatives lenalidomide and 
pomalidomide (collectively known as IMiDs) has since been demonstrated for several haematological 
cancers such as multiple myeloma (23,24). The anti-proliferative and immunomodulatory effects of 
IMiDs have recently been linked to drug-induced ubiquitination and degradation of the transcription 
factors IKZF1 and IKZF3, two specific B cell transcription factors, involved in the onset of multiple 
myeloma (25,26). 
With respect to ENL and myeloma, thalidomide was approved for use by the US FDA in 1998 and 
2006, respectively (19). However, due to its serious teratogenicity, the prescription of thalidomide is 
strictly controlled by the System for Thalidomide Education and Prescribing Safety (STEPS) program 
(27). It is therefore very important to describe in detail the mechanism of action of the drug. In fact, 
the elucidation of the molecular basis of thalidomide teratogenicity can lead to the elimination of its 
side effects and to the development of thalidomide derivatives and related compounds devoid of 
teratogenic activity. Moreover, by further investigating the targets of thalidomide therapeutic activity, 
it may be possible to expand the spectrum of pathological conditions in which the drug can be used. 
However, despite the many efforts that were spent during the last 50 years trying to elucidate 
thalidomide mechanism of action, the details remain still elusive. Previous studies have proposed that 
thalidomide-induced oxidative stress might be at the basis of thalidomide teratogenicity (28,29). 
Another supported thesis states that thalidomide anti-angiogenic properties might mediate its 
teratogenic effects (21,30). Only recently has been identified a primary target for thalidomide 
teratogenicity: the thalidomide-binding protein CEREBLON (CRBN), which is a substrate receptor 
in the (31). However, the ubiquitously expressed CRBN protein cannot account alone for the tissue-
specificity of thalidomide teratogenicity and other components are likely to contribute to the effects 
of the drug. 
In the present study, we report that thalidomide is able to promote FBWX7 mediated ubiquitination 
and proteasome mediated degradation of ΔNp63α. To do so, it requires the activity of Glycogen 
Synthase Kinase 3 (GSK3), which phosphorylates ΔNp63α on residues S383 and threonine 397 
(T397), whose integrity is required for thalidomide action on ΔNp63α. Moreover, our data 
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demonstrate that thalidomide-induced downregulation of ΔNp63α in zebrafish embryos is at the basis 
of thalidomide-induced fin defects, providing a description of the molecular basis of thalidomide 
teratogenicity. 
 
Results 
Thalidomide induces Np63 degradation 
The phenotypic similarity between thalidomide-induced malformations and those due to mutations in 
p63 gene prompted us to determine whether p63 could be a molecular target of the drug. We treated 
human keratinocytes (HaCaT) cells, which endogenously express the Np63 isoform, with 
thalidomide (10 M). Indeed, thalidomide treatment resulted in a drastic decrease of Np63 protein 
expression levels (Fig. 1). RT-PCR performed on total RNA from these cells revealed that 
thalidomide-induced Np63 protein downregulation was not accompanied by a decrease in p63 
mRNA levels, indicating that thalidomide acts at a protein level to modulate Np63 expression (Fig. 
2). In order to understand how the drug induces a decrease in Np63 levels, we treated HaCaT cells 
with thalidomide in the presence or absence of the proteasome inhibitor MG132 (5 M). Interestingly, 
the treatment with MG132 blocked the effects of thalidomide on Np63 protein levels, indicating 
that thalidomide treatment induces proteasome-mediated degradation of Np63 (Fig. 1). 
 
Thalidomide treatment alters the transcriptional activity of Np63 in a promoter-specific 
manner 
p63 is essential for epidermal differentiation and limb development. In order to assess the impact of 
thalidomide treatment on p63 downstream pathway(s), we treated HaCaT cells with thalidomide (10 
µM) and analysed by semi-quantitative RT-PCR the expression levels of a particular set of p63 target 
genes: IKKα, which is involved in epidermal development (32,33), PERP, which is essential for 
epithelial integrity (34), DLX5 and DLX6 which are downstream to p63 in the regulation of limb 
development (10) and REDD1, involved in the response to reactive oxygen species (35). Interestingly, 
upon thalidomide treatment, the transcription levels of the p63 target genes IKKα, PERP, DLX5 and 
DLX6 were drastically reduced, whilst the expression levels of REDD1 remained unaltered (Fig. 2), 
indicating that thalidomide-induced p63 degradation results specifically in an alteration of p63 
function on developmentally-related target genes. 
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Thalidomide treatment specifically induces the degradation of the ΔNp63α and ΔNp63β 
isoforms and requires the activity of FBWX7 E3 ubiquitin ligase and GSK3 kinase to promote 
the degradation 
The p53-related p63 gene can be transcribed in several isoforms that differ not only in their structure 
but also in function (13,36). In order to analyse the response of the different p63 isoforms to 
thalidomide, we transiently transfected human osteosarcoma (U2OS) cells, which do not 
endogenously express p63, with either ΔNp63α, ΔNp63β or ΔNp63γ isoforms and treated the cells 
with thalidomide (10 M). Thalidomide treatment efficiently leads to a downregulation of ΔNp63α 
and ΔNp63β isoforms but does not alter ΔNp63γ protein levels. Interestingly, thalidomide acts 
specifically on the p63 transcription factor, since the protein levels of NF-Y and p53 transcription 
factors were not altered by the treatment (Fig. 3A).  
The C-terminal region of p63 is absent in the ΔNp63γ isoform and therefore may be required for 
thalidomide-induced p63 degradation. To further narrow-down the region of p63 required for 
thalidomide action, we employed several truncated mutants of ΔNp63 with stop codon inserted at 
different positions within the common region shared by ΔNp63α and ΔNp63β isoforms (data not 
shown). Interestingly, in the region that was found to be necessary for mediating thalidomide-induced 
degradation were present two residues, S383 and T397, which we previously identified as important 
sites for p63 degradation (5,7). To verify whether these two residues are involved in thalidomide-
induced degradation, we treated with thalidomide (10 µM) U2OS cells transfected with either the 
ΔNp63αS383A, the ΔNp63αT397A or the ΔNp63αS383A/T397A mutants. Interestingly, the single 
mutants ΔNp63αS383A and ΔNp63αT397A appeared to be partially resistant to thalidomide 
treatment, whilst the double mutant ΔNp63αS383A/T397A was completely resistant (Fig. 3B). 
S383 and T397 residues are centered on two predicted phosphodegrons for the FBWX7 E3 ubiquitin 
ligase, which promotes the degradation of ΔNp63α and ΔNp63β isoforms upon DNA damage or 
keratinocytes differentiation.  FBWX7 binds to its targets in a phosphorylation-dependent manner 
and most of its known substrates are phosphorylated by GSK3 (7). 
Strikingly, silencing of endogenous FBWX7 in HaCaT cells abolished ΔNp63α protein modulation 
upon thalidomide treatment (Fig. 4A). Moreover, inhibition of GSK3 kinase activity with the specific 
inhibitor SB216763 (10 µM) led to a complete resistance of ΔNp63α protein to thalidomide treatment 
(Fig. 4B), indicating that the thalidomide-induced downregulation of ΔNp63α is mediated by the 
activity of FBWX7 E3 ubiquitin ligase and GSK3 kinase. 
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Thalidomide treatment downregulates p63 protein levels in vivo in zebrafish embryos 
Thalidomide, along with its anti-angiogenic, anti-neoplastic and anti-rheumatic properties, displays 
dangerous teratogenic effects. In particular, thalidomide is teratogenic in rabbits and chicks, but not 
in mice and rats. Recently, thalidomide was reported to be teratogenic in zebrafish where it causes 
severe reduction in the length of pectoral fins, which are homolog structures to tetrapod limbs with 
respect to early patterning and gene expression (31,37). In order to verify in an in vivo model whether 
thalidomide treatment results in a downregulation of p63 protein levels, we treated zebrafish embryos 
with thalidomide (400 µM) and allowed them to grow for 24, 48 or 72 hours post fertilization (hpf). 
Indeed, thalidomide treatment induces a downregulation of p63 protein levels in zebrafish embryos 
along with a severe impairment of pectoral fin development (Fig 5A). p63 is an important regulator 
of correct fin development also in zebrafish (38–40). To further characterize the effects of thalidomide 
on the fin developmental pathway which is downstream to p63, we analysed the protein levels of dlx5 
which is a p63 target gene involved in the development of zebrafish pectoral fins (10,40). 
Interestingly, protein levels of dlx5 were reduced in zebrafish embryos treated with thalidomide 
(400µM) (Fig. 5B), suggesting that thalidomide-induced downregulation of p63 results in a general 
impairment of the downstream fin developmental pathway.  
 
Thalidomide-induced defects are rescued by p63 overexpression in zebrafish embryos 
In order to verify whether the reduction of p63 protein levels could be linked to thalidomide 
tereatogenicity, we microinjected either zp63-mRNA or control-mRNA into zebrafish embryos that 
were subsequently treated with thalidomide (400 µM) and let them develop for 72 hpf.   
Strikingly, the injection of zp63-mRNA was able to rescue the thalidomide-induced defects in 
pectoral fin development, observed in the embryos injected with control-mRNA (Fig. 6A, 6B). This 
result strongly suggests that the restoration of normal p63 levels is able to rescue the phenotypical 
defects induced by thalidomide treatment in fin development. 
Furthermore, to verify if the phenotypical rescue that we obtained by microinjecting  zp63-mRNA 
was accompanied by a general restoration of the fin developmental pathway, we analysed by Real-
Time qPCR the expression levels of tbx5a and prrx1a, two genes essential for correct fin development 
in zebrafish embryos (41–43). Our analysis on total RNA from zebrafish embryos at 49 hpf revealed 
that the microinjection of zp63-mRNA is able to restore the levels of tbx5a and prxx1a transcript 
otherwise altered by thalidomide treament (Fig. 6C).  
All these results indicate that the restoration of p63 levels can rescue thalidomide-induced alterations 
in fin development both at a phenotypical and at a molecular level, suggesting that thalidomide-
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induced teratogenesis is indeed mediated by p63 protein downregulation, which perturbs the 
downstream developmental pathway. 
 
Discussion 
Here we report that thalidomide is able to induce developmental defects by promoting protesome-
mediated degradation of ΔNp63α and demonstrate that ΔNp63α is a new molecular target of 
thalidomide teratogenicity.  
p63 transcription factor plays a key role in limb development and p63-/- mice display absence or severe 
truncations of the limbs (1,2). Moreover, mutations in p63 gene can cause several syndromic or non-
syndromic conditions, some of them characterized by severe defects in the limbs, such as ectrodactyly 
and syndactyly (13,14). The clinical features of patients affected by these mutations are very 
reminiscent of thalidomide-induced defects. Indeed, it has occurred that EEC patients have been 
wrongly referred as possible victims of thalidomide (15). 
Thalidomide causes multiple birth defects of the ear, eye, internal organs, and central nervous system 
but the most frequent malformations induced by the drug are by far phocomelia and amelia (16–18). 
These two pathological conditions consist, respectively, in the severe shortening or in the complete 
absence of legs and/or arms. 
Since the first discovery of thalidomide teratogenic effects in 1961, numerous efforts were made 
trying to understand the molecular mechanisms of action of the drug. It was proposed that thalidomide 
teratogenic activity is linked to its ability to inhibit bFGF-induced angiogenesis; thalidomide 
antiangiogenic effects might be at the basis of limb defects, since blood vessel formation is crucial 
for limb development (21). In 1999, Parman et al. suggested that thalidomide causes limb deformities 
through a mechanism involving oxidative stress; thalidomide generates reactive oxygen species 
(ROS) and oxidative stress might downregulate essential limb growth factors (28,29). 
However, only recently it has been identified a primary target for thalidomide teratogenicity: the 
thalidomide-binding protein CEREBLON (CRBN), which is a substrate receptor in the E3 ubiquitin 
ligase complex CRL4 (31). Ito et al. proposed that thalidomide causes limb malformations by 
inhibiting CRBN E3 ubiquitin ligase activity. CRBN has an important role in central nervous system 
development, especially in memory and learning and is linked to Autosomal Recessive 
NonSyndromic mild Mental Retardation (ARNSMR) (44). Nevertheless, there is no evidence of a 
primary role for the ubiquitously expressed CRBN protein in limb development. Therefore, CRBN 
can hardly account alone for the tissue-specificity of thalidomide teratogenicity and other components 
are likely to contribute to the effects of the drug.  
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Our results indicate that thalidomide treatment is able to induce teratogenicity by reducing ΔNp63α 
protein levels, both in vitro and in vivo. Based on our data, we propose a model in which thalidomide 
is able to promote ΔNp63α ubiquitination through the action of the E3 ubiquitin ligase FBWX7, 
consequently leading to the proteasomal degradation of ΔNp63α and to a downregulation of its target 
genes. To induce ΔNp63α degradation, thalidomide requires the activity of GSK3 kinase which 
phosphorylates p63 on residues S383 and T397 and this phosphorylation is recognized as a signal by 
FBWX7 (Fig.7).  
Thalidomide, by altering the otherwise tightly regulated levels of p63, overall disregulates the 
pathways that drive the development of zebrafish pectoral fins and perturbs the expression levels of 
p63 targets involved in development such as dlx5. 
Most importantly, we demonstrate that the microinjection of p63-mRNA into 2-cells stage zebrafish 
embryos phenotypically rescues thalidomide-induced alterations in fin formation. Moreover, this 
phenotypical rescue is accompanied at a molecular level by a restoration of normal expression levels 
of tbx5a and prrx1a, two genes essential for correct fin development in zebrafish embryos (41–43), 
indicating that the microinjection of p63-mRNA is sufficient and necessary to readjust the general 
perturbation induced by thalidomide in fin development.  
All these data indicate that thalidomide-induced p63 downregulation is at the basis of the fin defects 
induced by the drug.  
However, there is no clear evidence of a direct interaction between thalidomide and ΔNp63α. It is 
possible that thalidomide primary target CRBN can mediate the effect of the drug on ΔNp63α. 
It is also possible that thalidomide acts on ΔNp63α independently from CRBN, by directly binding 
to ΔNp63α, GSK3 kinase and/or FBWX7 ubiquitin ligase. Thalidomide might, for example, facilitate 
the interaction between FBWX7 E3 ubiquitin ligase and ΔNp63α, inducing ΔNp63α ubiquitination 
and consequent degradation. Fisher et al. suggested a similar mechanism for the lenalidomide-
induced degradation of IKZF1 and IKZF3, two essential factors in the onset of multiple myeloma; 
the thalidomide analogue lenalidomide is able to bring IKZF1 and IKZF3  in the vicinity of CRL4 
CRBN E3 ubiquitin ligase, thus promoting their ubiquitination (45).  
The employment of thalidomide in the treatment of multiple myeloma and leprosy (20,23) requires a 
precise description of its molecular mechanism of action. A better understanding of thalidomide 
mechanism of action might allow a rational design of novel related compounds with equal therapeutic 
properties but devoid of thalidomide teratogenic activity.  
The present work demonstrates that thalidomide induces limb/fin defects by reducing ΔNp63α protein 
levels, providing a fundamental missing piece in the description of the molecular mechanisms at the 
basis of thalidomide teratogenicity.  
Part III 
86 
 
Moreover, the capability of thalidomide to downregulate ΔNp63α protein levels has a therapeutic 
relevance per se. In fact, despite its pivotal role in development, ΔNp63α was also shown to be 
involved in several types of cancer such as squamous cell carcinoma (SCC), pediatric neuroblastoma 
and osteosarcoma (46,47). It is demonstrated that, in these pathological conditions, ΔNp63α 
upregulation induces the expression of crucial angiogenic factors and promotes tumour development. 
Moreover, cells overexpressing ΔNp63α display a selective advantage in osteorsarcoma metastasis, 
underlining ΔNp63α central role in the tumour progression and dissemination (46). 
Thus, our discovery of the effects of thalidomide on ΔNp63α levels not only clarifies the molecular 
mechanisms of thalidomide teratogenic effects on limb/fin development, but also paves the way for 
a potential powerful use of thalidomide and its derivatives in the treatment of neoplastic conditions 
where ΔNp63α is overexpressed. 
 
Experimental procedures 
Plasmids 
All expression vectors encoding p63 cDNAs have been previously described (48). The shLUC, 
shFBWX7 and ΔNp63αS383A/T397A constructs also have been previously described (7,49). 
 
Cell culture, transfection and treatments 
U2OS and HaCaT cells were kept in DMEM supplemented with 10% FBS (Euroclone) at 37°C in a 
humified atmosphere of 5% (v/v) CO2 in air. For transient transfection, 50000 cells were seeded into 
24-multiwell plates and on the next day transfected with Lipofectamine 2000 (Invitrogen) or 
Lipofectamine LTX (Invitrogen) for HaCaT cells, under the conditions suggested by the 
manufacturer. Transfection efficiency was checked by transfection of β-gal or GFP expression 
vectors. The total amount of transfected DNA (500 ng for 50 000 cells) was kept constant using empty 
vector as necessary. U2OS and HaCaT cells were treated with 10 μM thalidomide (Sigma-Aldrich), 
10 μM SB216763 (Sigma-Aldrich) or 5 μM MG132 (Sigma-Aldrich) for the indicated times. 
 
Zebrafish maintenance and treatments  
Current Italian national rules: no approval needs to be given for research on zebrafish embryos. Wild-
type zebrafish of the AB strain were raised and maintained according to established techniques (50). 
Embryos were collected by natural spawning. Thalidomide treatment was performed as previously 
described (31). 
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Western blot and antibodies 
24 h after transfection or at the indicated times after treatments, cells were lysed in 100 μl of Loading 
Buffer 2X (2% sodium dodecyl sulfate, 30% glycerol, 144 mM β-mercaptoethanol, 100 mM Tris HCl 
pH 6.8 and 0.1% Bromo-Phenol Blue).  
Zebrafish total extracts were obtained by mechanical disgregation of the embryos into RIPA Buffer 
(50 mM Tris HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1% NP-40, 0.5% sodium deoxycholate). 
PMSF and cocktail protease inhibitors (Sigma-Aldrich) were added according to the manufacturer's 
instruction.  
Cell and zebrafish embryo samples were incubated at 98°C for 10 min and resolved by SDS-PAGE. 
Proteins were transferred to a nitrocellulose membrane (Protran, Millipore). The blots were incubated 
with the following antibodies: p63 (mouse monoclonal 4A4 sc-8431, Santa Cruz Biotechnology), 
dlx5 (goat polyclonal Y-20 sc-18151, Santa Cruz Biotechnology), p53 (mouse monoclonal DO1, 
Genespin) and actin (A2066, Sigma), NF-YA (rabbit polyclonal sc-10779, Santa Cruz 
Biotechnology). We used the following secondary antibodies: goat α-mouse (sc-2005, Santa Cruz 
Biotechnology), goat α-rabbit (sc-2030, Santa Cruz Biotechnology) and rabbit α-goat (sc-2768, Santa 
Cruz Biotechnology). Proteins were visualized by an enhanced chemi-luminescence method (Biorad) 
according to manufacturer’s instructions.  
 
Microinjection of capped mRNAs 
Microinjection into one-cell stage embryos was carried out as previously described (51) using a 
nitrogen gas-pressure microinjector IM 300 (Narishige) at 15 picosiemens for 30-50 ms. Capped 
mRNAs were synthesized in vitro using the mMESSAGE mMACHINE SP6 in vitro transcription kit 
(Ambion). RNAs were dissolved in nuclease-free water at 350 ng/μl immediately before use. 
 
RNA extraction and RT-PCR  
Total RNA was extracted from HaCaT cells using the TRI-Reagent (Sigma), as indicated by the 
supplier. 1 μg of RNA was reverse-transcribed using SuperScript III (Life Technology), following 
the manufacturer’s instuctions. Total cDNA was used for amplification with the primers described in 
Table 1. GAPDH mRNA was used for normalization. 
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RNA extraction and Real-Time qPCR from zebrafish extracts 
Total RNA was extracted from zebrafish embryos at 49 hpf using NucleoSpin®  
RNA XS (MACHEREY-NAGEL) as indicated by the supplier. 1 μg of RNA was reverse-transcribed 
using SuperScript III (Life Technology), following the manufacturer’s instuctions. Real-Time 
quantitative PCR (qPCR) was performed with SybrGreen supermix (Biorad). GAPDH mRNA was 
used for normalization. The sequences of the primers are reported in Table 2. 
 
 
Table 1. Primers for semi-quantitative RT-PCR on HaCaT cell extracts  
 Forward Reverse 
ΔNp63α 5’-GTCTCCATCTTCATATGGTAA-3’ 5’-CACACTGACTGTAGAGGCA-3’ 
DLX5 5’-CTACAACCGCGTCCCAAG-3’ 5’-CACCTGTGTTTGTGTCAATCC-3’ 
DLX6 5’-CCTCGGACCATTTATTCCAG-3’ 5’-TTGTTCTGAAACCATATCTTCACC-3’ 
IKKα 5’-TTCGGGAACGTCTGTCTGTACC-3’ 5’-GGTTTGTTGAGCAGCTTTCGGAG-3’ 
GAPDH 5’-TCACCAGGGCTGCTTTTAAC-3’ 5’-TGGAAGATGGTGATGGGATT-3’ 
PERP 5’-GTGGAAATGCTCCCAAGAGG-3’ 5’-TCCAATCACTCCAGGAAGACA-3’ 
REDD1 5’-GAACTCCCACCCCAGATCGG-3’ 5’-CGAGGGTCAGCTGGAAGGTG-3’ 
 
Table 2. Primers for Real-Time qPCR on zebrafish extracts  
 Forward Reverse 
gapdh 5’-CGCTGGCATCTCCCTCAA-3’ 5’-TCAGCAACACGATGGCTGTAG-3’ 
tbx5a 5’-CCACTGCATCAAGAGGAAAGT-3’ 5’-CCACATACGGCTTCTTCTTATAGGG-3’ 
prrx1a 5’-AGCGACACTACACAGCAGGA-3’ 5’-CGCCTCTGTTTACGCTTCT-3’ 
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Figure legends 
Figure 1. The ΔNp63α protein is downregulated by thalidomide treatment in human keratinocytes. 
Western Blot (WB) analysis of whole HaCaT cell extracts treated with DMSO, 5 µM MG132, 10 µM 
thalidomide, or 10 µM thalidomide concomitantly with 5 µM MG132, for the indicated times. 
 
Figure 2. Expression of ΔNp63α and of its target genes in HaCaT cells upon thalidomide treatment. 
RT-PCR semiquantitative analysis of ΔNp63α, REDD1, IKKα, PERP, DLX5 and DLX6 mRNAs on 
whole HaCaT cell extracts treated with DMSO or 10 µM thalidomide for the indicated times. GAPDH 
mRNA was used for normalization. 
 
Figure 3. Thalidomide degrades specifically isoforms ΔNp63α and ΔNp63β and requires integrity of 
S383 and T397 residues. (A) WB analysis of whole extracts from U2OS cells transiently co-
transfected with either ΔNp63α, ΔNp63β or ΔNp63γ expression vectors (30 ng) and then treated with 
DMSO or 10 µM thalidomide for the indicated times. Endogenous NF-Y and p53 protein levels are 
also shown. (B) WB analysis of whole extracts from U2OS cells transiently transfected with either 
ΔNp63α or ΔNp63αS383A-T397A mutant expression vectors (30 ng) and then treated with DMSO 
or 10 µM thalidomide for the indicated times. 
 
Figure 4. Thalidomide requires FBWX7 and GSK3 activity. (A) WB analysis of whole HaCaT cell 
extracts transiently transfected with shFBWX7 or shLUC (40 ng) and treated with DMSO or 10 µM 
thalidomide for the indicated times. (B) WB analysis of whole HaCaT cell extracts treated with 
DMSO, 10 μM SB216763, 10 µM thalidomide or 10 µM thalidomide concomitantly with 10 μM 
SB216763. 
 
Figure 5. Thalidomide downregulates p63 and its target dlx5 in zebrafish embryos. (A) WB analysis 
of whole zebrafish embryos extracts treated with DMSO or 400 µM thalidomide. The embryos were 
analysed for p63 protein expression levels at the stages of 24, 48 and 72 hpf. (B) WB analysis of 
whole zebrafish embryos extracts treated with DMSO or 400 µM thalidomide. The embryos were 
analysed for dlx5 protein expression levels at the stage of 48 hpf.  
 
Figure 6. Microinjection of zp63-mRNA is able to rescue thalidomide-induced defects both at a 
phenotypical and at a molecular level. (A) Dorsal views of pectoral fins of 72-hpf embryos treated 
with DMSO or 400 µM thalidomide. Pectoral fins are indicated by arrowheads. Green arrowheads 
Part III 
94 
 
indicate normal fins, red arrowheads indicate short fins. Where indicated, egfp-mRNA or egfp:zp63-
mRNA was injected into one-cell stage embryos. (B) Percentage of embryos treated with DMSO or 
400 µM thalidomide displaying Normal, Mild or Severe phenotype. Where indicated, egfp-mRNA or 
egfp:zp63-mRNA was injected into one-cell stage embryos. The embryos were classified on the basis 
of the pectoral fins length. Normal class embryos displayed normal fins, Mild class embryos 
displayed shorter, non-protruding fins, Severe class embryos did not display a proper fin fold but a 
fin bud, or complete absence of the fin.  (C) Expression of tbx5a and prrx1a was analyzed by Real-
Time qPCR in zebrafish embryos at 49 hpf treated with DMSO or thalidomide. Where indicated, 
egfp-mRNA or egfp:zp63-mRNA was injected into one-cell stage embryos. 
 
Figure 7. Np63 is a molecular target of thalidomide teratogenicity. Based on our data, we propose 
a model in which thalidomide induces teratogenicity by promoting a series of ΔNp63α post-
translational modifications that lead to the proteasomal degradation of the protein. To induce ΔNp63α 
degradation, thalidomide requires the activity of GSK3 kinase which phosphorylates p63 on residues 
S383 and T397 and this phosphorylation is recognized as a signal by FBWX7. Thalidomide-induced 
ΔNp63α degradation leads to a lack of activation of ΔNp63α target genes involved in limb/fin 
development, such as dlx5.  
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CRBN is a negative regulator of ΔNp63α protein 
Introduction 
In the last 50 years many efforts were spent trying to unravel the molecular mechanism of action of 
the teratogenic drug thalidomide.  
Only in 2010 Ito et al. identified the primary target of thalidomide teratogenicity. By employing high-
performance affinity ferriteglycidyl methacrylate (FG) beads, covalently conjugated to the carboxylic 
thalidomide derivative FR259625, they were able to purify from HeLa cell extracts a direct target of 
thalidomide drug. By mass spectrometry, it was possible to identify this protein as CEREBLON 
(CRBN), a protein made up of 442 amino acids, evolutionarily conserved from plants to humans (1). 
CRBN was first reported in 2004 and was originally identified as an Autosomal Recessive 
NonSyndromic mild Mental Retardation (ARNSMR) gene, which is located at 3p25-pter and plays 
an important role in central nervous system development, being involved in memory and learning 
(2,3). However, CRBN also possesses intrinsic ubiquitination activity and co-precipitates with all the 
components of the Cullin 4 (CUL4)-based E3 ubiquitin protein ligase complex. CRBN is a subunit 
of the CUL4-based E3 ubiquitin ligase complex where it functions as a substrate receptor (1). CUL4-
based E3 ubiquitin ligases have been shown to be important for DNA repair (4–10), DNA replication 
(11–14), transcription (15) and development (1).  
Thalidomide is able to inhibit CRBN autoubiquitination in vitro, suggesting that thalidomide is an 
inhibitor of its E3 ubiquitin ligase activity. The CRBN Y384A/ W386A (CRBNYW/AA) double point 
mutant, unable to bind to thalidomide, does not display loss of autoubiquitination activity upon drug 
treatment, suggesting that thalidomide inhibits E3 function of the CRBN-containing complex by 
directly binding to CRBN. In vivo studies on zebrafish embryos revealed that the microinjection in 2 
cells-stage embryos of the mRNA encoding for CRBN Y384A/ W386A, rescues the defects otherwise 
induced by thalidomide in ear and pectoral fin development (1).  
Collectively, all these pieces of evidence suggest that thalidomide exerts its teratogenic effects by 
binding to CRBN and inhibiting its function, indicating that CRBN is a primary target of thalidomide 
teratogenicity. In particular, it was proposed that thalidomide initiates teratogenic effects by inhibiting 
CRBN E3 ubiquitin ligase function, leading to the accumulation of unknown substrates that might be 
negative regulators of essential factors that drive correct limb/fin development, such as fgf8 (1). 
In 2013 it has been demonstrated that also thalidomide analogue lenalidomide is able to bind CRBN 
protein and this binding mediates the therapeutic effects of the drug against Multiple Myeloma (MM), 
a malignancy of immunoglobulin producing plasma cells. Lu et al. and Krönke et al. demonstrated 
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that, after direct binding, lenalidomide is able to activate the E3 ligase activity of CRBN, which 
acquires the ability to selectively target for proteasomal degradation the zinc finger-containing 
transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), which are highly expressed in B cell 
malignancies, including MM (16–21). 
Studies on the crystallized structure of Gallus gallus (chicken) CRBN bound to thalidomide or 
lenalidomide revealed that the drugs bind to CRBN at the canonical substrate-binding site. As 
thalidomide and lenalidomide occupy the binding site of CRBN, they simultaneously confer to the 
E3 complex new substrate specificity while interfering with the recruitment of endogenous substrates 
(22). Therefore thalidomide and lenalidomide appear to be not only CRBN antagonists, as proposed 
by Ito et al. (1), instead, they more generally alter the substrate specificity of CRBN to include 
proteins important in MM. 
 
Rationale  
CRBN is a primary target of thalidomide teratogenicity (1). However, the highly conserved and 
ubiquitously expressed CRBN protein cannot account alone for the species-specificity and tissue-
specificity of thalidomide teratogenicity and other components, perhaps downstream targets of 
CRBN, are likely to contribute to the effects of the drug. Moreover, the CRBN substrates that mediate 
the teratogenic cascade initiated by thalidomide have not been identified yet. 
p63 is a key regulator of limb/fin development (23–26) and in the previous chapter we reported that 
it is an essential mediator of thalidomide teratogenicity. We proposed that thalidomide leads to 
FBWX7-mediated degradation of p63 and that thalidomide-induced depletion of p63 is both 
sufficient and necessary for the drug to initiate its teratogenic effects (Molinari et al., in preparation). 
However, it is not clear whether thalidomide directly interacts with p63 or its action on p63 is 
mediated by other components. We here aim at elucidating if CRBN is involved in mediating 
thalidomide-induced downregulation of p63 and if p63 is a substrate of CRBN E3 ubiquitin ligase 
activity. 
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Results 
 
CRBN overexpression leads to ΔNp63α proteasome-mediated degradation 
In order to assess whether ΔNp63α could be a substrate of thalidomide direct target CRBN, we 
transfected in human osteosarcoma (U2OS) cells, which do not endogenously express p63, the 
ΔNp63α isoform together with increasing quantities of CRBN. Overexpression of CRBN results in a 
dose-dependent decrease of ΔNp63α protein levels. Interestingly, this effect was blocked when the 
cells where concomitantly treated with the proteasome inhibitor MG132, suggesting that the 
overexpression of CRBN promotes a proteasome-mediated degradation of ΔNp63α (Fig. 1A). On the 
contrary, transient silencing of CRBN in U2OS cells, transfected with ΔNp63α, resulted in an 
upregulation of ΔNp63α protein levels (Fig. 1B), confirming that CRBN acts as a negative regulator 
on ΔNp63α. 
 
 
 
Figure 1. CRBN overexpression leads to ΔNp63α proteasome-mediated degradation. (A) The ΔNp63α protein is 
downregulated by CRBN overexpression in human U2OS. Western Blot (WB) analysis of whole U2OS cell extracts 
transiently co-transfected with ΔNp63α (30 ng) and increasing quantities (30, 60, 90 ng) of CRBN expression vectors and 
then treated with DMSO (left) or 5 µM MG 132 (right). (B) The ΔNp63α protein is upregulated upon CRBN silencing. 
WB analysis of whole U2OS cell extracts transiently co-transfected with ΔNp63α and shCRBN or shLUC. 
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CRBN overexpression specifically induces protein downregulation of ΔNp63α and ΔNp63β but 
not of ΔNp63γ  
In order to analyse the response of the different p63 isoforms to CRBN overxpression, we transiently 
transfected U2OS cells with either ΔNp63α, ΔNp63β or ΔNp63γ isoforms together with increasing 
quantities of CRBN. CRBN overexpression resulted in a dose-dependent reduction of ΔNp63α and 
ΔNp63β, but not of ΔNp63γ (Fig. 2A). Very interestingly, ΔNp63γ resistance to CRBN 
overexpression reflects ΔNp63γ resistance to thalidomide treatment (see previous chapter), indicating 
that the C-terminal missing portion in ΔNp63γ is required both for thalidomide- and CRBN-induced 
p63 downregulation. 
Moreover, CRBN overexpression was found able to alter specifically the levels of p63 transcription 
factor, since the protein levels of p53 did not change in presence of increasing quantities of CRBN 
(Fig 2B).  
 
 
 
Figure 2. CRBN overexpression specifically induces protein downregulation of ΔNp63α and ΔNp63β isoforms. (A) WB 
analysis of whole extracts from U2OS cells transiently co-transfected with either ΔNp63α, ΔNp63β (30 ng) or ΔNp63γ 
(15 ng) expression vectors and with increasing quantities (30, 60, 90 ng) of CRBN expression vector. (B) CRBN 
overexpression efficiently induces ΔNp63α protein downergulation, whilst it does not alter the levels of p53 protein. 
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Crbn knockdown results in an upregulation of p63 protein in zebrafish embryos  
To confirm whether crbn is able to perturb p63 protein levels also in vivo, we transiently knocked 
down zcrbn in zebrafish embryos by microinjecting a zcrbn-specific morpholino (zcrbn-MO) and let 
the embryos develop for 72 hours post fertilization (hpf). The morphant embryos displayed mild fin 
defects in a zcrbn-MO dose-dependent manner (Fig. 3A, 3B), similarly as previously showed by Ito 
et al. (1). We then checked the protein levels of p63 from control and morphant whole embryos 
extracts. Interestingly, also in zebrafish embryos, the knockdown of crbn is able to promote a dose-
dependent upregulation of p63 protein, indicating that crbn acts as a negative regulator of p63 also in 
vivo in zebrafish embryos (Fig. 3C). 
 
 
 
Figure 4. Crbn knockdown results in an upregulation of p63 protein in zebrafish embryos. (A) Microinjected embryos 
with zcrbn-MO displayed mild fin defects in a dose-dependent manner. Dorsal views of pectoral fins of 72 hpf embryos. 
The embryos were classified on the basis of the pectoral fins length. Normal class embryos displayed normal fins, Mild 
class embryos displayed shorter, non-protruding fins, Severe class embryos did not display a proper fin fold but a fin bud, 
or complete absence of the fin.  (B) Percentage of embryos displaying Normal, Mild or Severe phenotype for each dose 
of control-MO (Std-MO) or zcrbn-MO injected. (C) WB analysis of whole extracts from zebrafish embryos microinjected 
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with Std-MO or with increasing doses of zcrbn-MO. The embryos were analysed for p63 protein expression levels at the 
stage of 72-hpf.  
Mouse CRBN is not able to induce ΔNp63α protein downregulation in murine cells 
Thalidomide is able to induce developmental malformations in human, chimps, rabbit, chicken and 
zebrafish but not in mouse and rat and the reasons for the species-specificity of thalidomide 
teratogenicity are still unknown (27). CRBN is highly conserved from fish to mammals and the 
residues Y384 and W386, identified by Ito et al. as responsible for thalidomide binding (1), are also 
present in the murine protein. Thus, CRBN alone can hardly explain the species-specificity of 
thalidomide teratogenicity and it is possible that other molecules, perhaps downstream targets of 
CRBN, may define the specificity of thalidomide teratogenicity. 
We raised the hypothesis that the species-specificity of thalidomide teratogenicity might be explained 
by the differential ability of CRBN orthologues from different species to induce ΔNp63α protein 
downregulation. To test this hypothesis we firstly expressed in U2OS cells ΔNp63α together with 
increasing quantities of either Homo sapiens (human) or Mus musculus (mouse) CRBN. The human 
and mouse CRBN orthologues did not display differential efficiency in inducing ΔNp63α 
downregulation (Fig. 4A). However, when we repeated the experiment in a murine context, by 
overexpressing either human or mouse CRBN in ΔNp63α transfected murine embryo fibroblasts NIH 
3T3 cells, mouse CRBN displayed a significant lower efficiency in promoting ΔNp63α 
downregulation compared to its human orthologous (Fig. 4B).  
 
 
Figure 5. Mouse CRBN is not able to induce ΔNp63α protein downregulation in murine cells. (A) WB analysis of whole 
extracts from U2OS cells transiently co-transfected with ΔNp63α (30 ng) and increasing quantities (30, 60, 90 ng) of 
either human (Hs) or mouse (Mm) CRBN expression vectors. (B) WB analysis of whole extracts from NIH 3T3 cells 
transiently co-transfected with ΔNp63α (30 ng) and increasing quantities (30, 60, 90 ng) of either human (Hs) or mouse 
(Mm) CRBN expression vectors 
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Human and mouse CRBN display a differential ability to interact with ΔNp63α in a murine 
context 
In order to verify if the effect of CRBN on ΔNp63α levels is due to a physical interaction between 
the two proteins, we transfected U2OS cells with ΔNp63α, together with either human or mouse 
CRBN, immunoprecipitated HA-CRBN from these cell extracts and checked whether ΔNp63α was 
able to co-immunoprecipitate with CRBN. Indeed, ΔNp63α co-immunoprecipitated with both human 
and mouse CRBN (Fig. 5A). We then repeated the same assay in NIH 3T3 cells. In murine context, 
ΔNp63α  displayed a strikingly reduced ability to co-immunoprecipitate with mouse CRBN, whilst it 
still efficiently interacted with human CRBN (Fig. 5B).  
Should ΔNp63α be a downstream target of CRBN in thalidomide teratogenic cascade, the differential 
ability of CRBN orthologues from different species to interact with ΔNp63α might provide a hint into 
the species-specificity of thalidomide teratogenicity.  
 
 
 
Figure 5. ΔNp63α and CRBN belong to the same immunocomplex. (A) U2OS whole cell extracts transiently co-
transfected with ΔNp63α (10 µg) and either mouse (Mm) or human (Hs) HA-CRBN (10 µg) were analyzed by 
immunoprecipitation with anti-HA antibody followed by WB analysis with anti-p63 antibody. U2OS cells not transfected 
were used as negative control. (B) NIH 3T3 whole cell extracts transiently co-transfected with ΔNp63α (10 µg) and either 
mouse (Mm) or human (Hs) HA-CRBN (10 µg) were analyzed by immunoprecipitation with anti-HA antibody followed 
by WB analysis with anti-p63 antibody. NIH 3T3 cells not transfected were used as negative control.  
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Discussion and future perspectives 
CRBN is the only direct target of thalidomide identified so far (1). However, the highly conserved 
and ubiquitariously expressed CRBN protein can hardly explain alone the species- and tissue-
specificity of thalidomide teratogenicity and other components are likely to be involved in the 
teratogenic process. 
Ito et al., proposed that thalidomide initiates its teratogenic effects by inhibiting CRBN ubiquitin 
ligase activity on unknown substrates that might be negative regulators of factors essential for 
limb/fin development, such as fgf8 (1). Nevertheless, the direct substrates of CRBN in the teratogenic 
cascade have not been identified yet.   
We showed in the previous chapter that ΔNp63α is a target of thalidomide teratogenicity, as 
thalidomide induces a reduction of ΔNp63α protein levels in vitro and in vivo and this effect is, at 
least in part, at the basis of the developmental defects induced by the drug (Molinari et al., in 
preparation). However, it is not clear how thalidomide induces a reduction of ΔNp63α; whether it 
directly acts on ΔNp63α or on other components upstream to ΔNp63α in the teratogenic cascade. 
The preliminary data that we are here reporting indicate that also CRBN is able to promote a 
downregulation of ΔNp63α protein. CRBN is a substrate receptor in CUL4-based E3 ubiquitin ligase 
complex (1). Our data are compatible with the hypothesis that ΔNp63α could be a substrate of CRBN 
ubiquitin ligase activity. Thalidomide, which is known to alter the activity and substrate specificity 
of CRBN (16,17,22), might promote a reduction of ΔNp63α protein levels by activating CRBN 
ubiquitin ligase activity towards ΔNp63α.  
ΔNp63α, which is an essential factor that drives correct limb and fin development, might represent a 
good candidate for mediating the teratogenic effects triggered by the binding of thalidomide to CRBN 
and could define the tissue-specificity of the malformations induced by the drug. Moreover, we found 
that, unlike its human orthologous, mouse CRBN is poorly efficient in co-immunoprecipitating with 
ΔNp63α and in inducing its downregulation in murine cells. Should ΔNp63α be a downstream target 
of CRBN in thalidomide teratogenic cascade, the differential sensitivity of ΔNp63α to CRBN 
orthologues from different species might explain the species-specificity of thalidomide teratogenicity. 
 
However, many questions remain to be addressed:  
a) does CRBN mediate thalidomide action on ΔNp63α? 
To verify if CRBN is indeed involved in thalidomide-induced degradation of ΔNp63α we plan to 
analyse the effects of thalidomide-treatment on ΔNp63α protein levels in cells where CRBN has been 
silenced or overexpressed.  
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b) does CRBN directly ubiquitinate ΔNp63α or does it act indirectly via a regulator of ΔNp63α 
stability?  
c) we showed in the previous chapter that thalidomide promotes p63 degradation via FBWX7 
ubiquitin ligase activity (Molinari et al., in preparation). Provided that CRBN contributes to 
thalidomide-induced ΔNp63α downregulation, does it interact with FBWX7 or does it function 
through an independent pathway? 
d) Finally, we plan to investigate the reasons of the reduced interaction between mouse CRBN and 
ΔNp63α protein in murine cells.  
 
Thalidomide is now used for treatment of MM and leprosy (28,29): a better understanding of its 
mechanism of action might pave the way for the design of related compounds with equal therapeutic 
properties but devoid of teratogenic activity. Moreover, it has been shown that the ability of 
thalidomide and its analogues to alter CRBN substrates specificity mediates not only the 
teratogenicity but also the therapeutic properties of these drugs (16,17,30). Therefore, elucidating 
whether ΔNp63α is a real substrate of CRBN and whether thalidomide is able to alter CRBN function 
on ΔNp63α might have a therapeutic relevance in those malignant conditions in which p63 is 
overexpressed. 
 
 
Experimental procedures 
 
Plasmids 
All expression vectors encoding p63 cDNAs have been previously described (31). The CRBN 
constructs have also been previously described (1). 
 
Cell culture, transfection and treatments 
U2OS cells were kept in DMEM supplemented with 10% FBS (Euroclone) at 37°C in a humified 
atmosphere of 5% (v/v) CO2 in air. For transient transfection, 50000 cells were seeded into 24-
multiwell plates and on the next day transfected with Lipofectamine 3000 (Invitrogen) under the 
conditions suggested by the manufacturer. Transfection efficiency was checked by transfection of β-
gal or GFP expression vectors. The total amount of transfected DNA (500 ng for 50 000 cells) was 
kept constant using empty vector as necessary. U2OS cells were treated with 5 μM MG132 (Sigma-
Aldrich) for 3 h. 
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Zebrafish maintenance and treatments  
Current Italian national rules: no approval needs to be given for research on zebrafish embryos. Wild-
type zebrafish of the AB strain were raised and maintained according to established techniques (32). 
Embryos were collected by natural spawning.  
 
Western blot and antibodies 
24 h after transfection, cells were lysed in 100 μl of Loading Buffer 2X (2% sodium dodecyl sulfate, 
30% glycerol, 144 mM β-mercaptoethanol, 100 mM Tris HCl pH 6.8 and 0.1% Bromo-Phenol Blue).  
Zebrafish total extracts were obtained by mechanical disgregation of the embryos into RIPA Buffer 
(50 mM Tris HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.1% NP-40, 0.5% sodium deoxycholate). 
PMSF and cocktail protease inhibitors (Sigma-Aldrich) were added according to the manufacturer's 
instruction.  
Cell and zebrafish embryo samples were incubated at 98°C for 10 min and resolved by SDS-PAGE. 
Proteins were transferred to a nitrocellulose membrane (Protran, Millipore). The blots were incubated 
with the following antibodies: p63 (mouse monoclonal 4A4 sc-8431, Santa Cruz Biotechnology) HA 
(rabbit polyclonal Y-11 sc-805, Santa Cruz Biotechnology), p53 (mouse monoclonal DO1, Genespin) 
and actin (A2066, Sigma). We used the following secondary antibodies: goat α-mouse (sc-2005, 
Santa Cruz Biotechnology) and goat α-rabbit (sc-2030, Santa Cruz Biotechnology). Proteins were 
visualized by an enhanced chemi-luminescence method (Biorad) according to manufacturer’s 
instructions.  
 
Microinjection of Morpholino  
Injections were carried out on 1–2 cell-stage embryos (Eppendorf FemtoJet Micromanipulator 5171); 
the dye tracer, rhodamine dextran, was co-injected. A standard control morpholino (Std-MO) 
oligonucleotide specific for human β-thalassemia was used. zcrbn antisense ATG morpholino (zcrbn-
MO) (Gene Tools) used in this study has been previously described (1).  
 
Co-immunoprecipitation 
U2OS cells (1.25 × 106/100mm plate) were transfected with the indicated vectors. 48 h after 
transfection, cells were harvested for whole-cell lysates preparation using RIPA buffer (10mM Tris–
HCl pH 8, 2mM EDTA, 0.1% SDS, 0.1% sodium deoxycholate, 140 mM NaCl, 1X Triton X-100, 
supplemented with 1mM phenylmethylsulfonylfluoride and cocktail protease inhibitors, Sigma). Cell 
lysates were incubated on ice for 20 min, vortexed, then centrifuged at 6600 g for 20 min to remove 
cell debris. Protein concentration was determined with the Bradford Reagent (Sigma). 2 mg of cell 
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lysates were incubated overnight at 4°C with 2 μg of anti-HA (rabbit polyclonal Y-11 sc-805, Santa 
Cruz Biotechnology). The immuno-complexes were collected by incubating with a mix of Protein A 
Agarose and Protein G Sepharose (Sigma) overnight at 4°C. The beads were washed three times: the 
first wash with RIPA buffer and the others with PBS. The beads were then resuspended in 2X Loading 
buffer, heated at 98°C and loaded on a SDS polyacrylamide gel and subjected to western blotting 
with the indicated antibodies. 
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